<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>ema-combined-h-660-en annotated</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-style:italic;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h4
	{margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h5
	{margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:12.0pt;
	layout-grid-mode:char;
	font-size:12.0pt;
	font-family:"HGMaruGothicMPRO",sans-serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.UnderlineSubheading, li.UnderlineSubheading, div.UnderlineSubheading
	{mso-style-name:"Underline Subheading";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.SPCSubHeading, li.SPCSubHeading, div.SPCSubHeading
	{mso-style-name:"SPC SubHeading";
	margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:.4in;
	text-indent:-.4in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.ItalicsSubheading, li.ItalicsSubheading, div.ItalicsSubheading
	{mso-style-name:"Italics Subheading";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.PackageLeafletSubheading, li.PackageLeafletSubheading, div.PackageLeafletSubheading
	{mso-style-name:"Package Leaflet Subheading";
	margin-top:11.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Proc1, li.Proc1, div.Proc1
	{mso-style-name:"Proc 1";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"HGMaruGothicMPRO",sans-serif;}
p.a, li.a, div.a
	{mso-style-name:a;
	mso-style-link:"Kommentarer Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.KommentarerChar
	{mso-style-name:"Kommentarer Char";
	mso-style-link:a;}
p.a0, li.a0, div.a0
	{mso-style-name:a0;
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.CommentaireCar
	{mso-style-name:"Commentaire Car";}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-weight:bold;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></h1>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon&nbsp;100&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon&nbsp;200&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon&nbsp;400&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Oral Tablet</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet
contains&nbsp;100&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet
contains&nbsp;200&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet
contains&nbsp;400&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients with known effect</span></u><span
lang=EN-GB>:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each&nbsp;100&nbsp;mg film&#8209;coated
tablet contains&nbsp;20&nbsp;mg lactose (as monohydrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>Each&nbsp;200&nbsp;mg film&#8209;coated
tablet contains&nbsp;40&nbsp;mg lactose (as monohydrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>Each&nbsp;400&nbsp;mg film&#8209;coated
tablet contains&nbsp;80&nbsp;mg lactose (as monohydrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated tablet.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>100&nbsp;mg: Pink, ‘ovaloid’, slightly
convex, approximately&nbsp;10.2&nbsp;mm in length, scored on both sides,
embossed ‘&#1028;261’ on one side and blank on the other side. The tablet can
be divided into equal halves.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>200&nbsp;mg: Pink, ‘ovaloid’, slightly
convex, approximately&nbsp;15.2&nbsp;mm in length, scored on both sides,
embossed ‘&#1028;262’ on one side and blank on the other side. The tablet can
be divided into equal halves.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>400&nbsp;mg: Pink, ‘ovaloid’, slightly
convex, approximately&nbsp;18.2&nbsp;mm in length, scored on both sides,
embossed ‘&#1028;263’ on one side and blank on the other side. The tablet can
be divided into equal doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.       CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon is indicated as adjunctive therapy
in the treatment of seizures associated with Lennox&#8209;Gastaut syndrome
(LGS) in patients&nbsp;1&nbsp;year of age and older.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.2     Posology and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with rufinamide should be
initiated by a physician specialised in paediatrics or neurology with
experience in the treatment of epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon oral suspension and Inovelon film&#8209;coated
tablets may be interchanged at equal doses. Patients should be monitored during
the switch over period.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Use in
children from&nbsp;1 year to less than&nbsp;4 years of age</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
not receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Treatment
should be initiated at a dose of&nbsp;10&nbsp;mg/kg/day administered in two
equally divided doses separated by approximately&nbsp;12&nbsp;hours. According
to clinical response and tolerability, the dose may be increased by up
to&nbsp;10&nbsp;mg/kg/day every third day to a target dose
of&nbsp;45&nbsp;mg/kg/day administered in two equally divided doses separated
by approximately&nbsp;12&nbsp;hours. For this patient population, the maximum
recommended dose is&nbsp;45&nbsp;mg/kg/day.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>As valproate
significantly decreases clearance of rufinamide, a lower maximum dose of
Inovelon is recommended for patients being co&#8209;administered valproate.
Treatment should be initiated at a dose of&nbsp;10&nbsp;mg/kg/day administered
in two equally divided doses separated by approximately&nbsp;12&nbsp;hours.
According to clinical response and tolerability, the dose may be increased by
up to&nbsp;10&nbsp;mg/kg/day every third day to a target dose
of&nbsp;30&nbsp;mg/kg/day administered in two equally divided doses separated
by approximately&nbsp;12&nbsp;hours. For this patient population, the maximum
recommended dose is&nbsp;30&nbsp;mg/kg/day.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If the
recommended calculated dose of Inovelon is not achievable, the dose should be
given to the nearest whole&nbsp;100&nbsp;mg tablet.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Use in
children&nbsp;4 years of age or older and less than&nbsp;30&nbsp;kg</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
&lt;&nbsp;30&nbsp;kg not receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Treatment
should be initiated at a daily dose of&nbsp;200&nbsp;mg. According to clinical
response and tolerability, the dose may be increased by&nbsp;200&nbsp;mg/day
increments, as frequently as every third day, up to a maximum recommended dose
of&nbsp;1,000&nbsp;mg/day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Doses of up to&nbsp;3,600&nbsp;mg/day have
been studied in a limited number of patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Patients &lt;&nbsp;30&nbsp;kg also
receiving valproate:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>As valproate significantly decreases
clearance of rufinamide, a lower maximum dose of Inovelon is recommended for
patients &lt;&nbsp;30&nbsp;kg being co&#8209;administered valproate. Treatment
should be initiated at a daily dose of&nbsp;200&nbsp;mg. According to clinical
response and tolerability, after a minimum of&nbsp;2&nbsp;days the dose may be
increased by&nbsp;200&nbsp;mg/day, to the maximum recommended dose
of&nbsp;600&nbsp;mg/day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Use in adults, adolescents and
children&nbsp;4 years of age or older of&nbsp;30&nbsp;kg or over</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Patients &gt;&nbsp;30&nbsp;kg not receiving
valproate:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Treatment should be initiated at a daily
dose of&nbsp;400&nbsp;mg. According to clinical response and tolerability, the
dose may be increased by&nbsp;400&nbsp;mg/day increments, as frequently as
every other day, up to a maximum recommended dose as indicated in the table
below.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Weight
  range</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30.0&nbsp;–&nbsp;50.0&nbsp;kg</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50.1&nbsp;–&nbsp;70.0&nbsp;kg</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&#8805;70.1&nbsp;kg</span></p>
  </td>
 </tr>
 <tr>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin-bottom:0in;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Maximum recommended dose </span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1,800&nbsp;mg/day</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2,400&nbsp;mg/day</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>3,200&nbsp;mg/day</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Doses of up to&nbsp;4,000&nbsp;mg/day (in
the&nbsp;30&nbsp;&#8209; &#8209;50&nbsp;kg range) or&nbsp;4,800&nbsp;mg/day (in
the over&nbsp;50&nbsp;kg) have been studied in a limited number of patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
&gt;&nbsp;30&nbsp;kg also receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Treatment
should be initiated at a daily dose of&nbsp;400&nbsp;mg. According to clinical
response and tolerability, the dose may be increased by&nbsp;400&nbsp;mg/day
increments, as frequently as every other day, up to a maximum recommended dose
as indicated in the table below.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:26.7pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Weight
  range</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30.0&nbsp;–&nbsp;50.0&nbsp;kg</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50.1&nbsp;–&nbsp;70.0&nbsp;kg</span></p>
  </td>
  <td width=136 valign=top style='width:102.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>&#8805;70.1&nbsp;kg</span></p>
  </td>
 </tr>
 <tr>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Maximum
  recommended dose</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1,200&nbsp;mg/day</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>1,600&nbsp;mg/day</span></p>
  </td>
  <td width=136 valign=top style='width:102.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2,200&nbsp;mg/day</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>There is
limited information on the use of rufinamide in older people. Since the
pharmacokinetics of rufinamide are not altered in older people (see section&nbsp;5.2),
dosage adjustment is not required in patients over&nbsp;65&nbsp;years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>A study in
patients with severe renal impairment indicated that no dose adjustments are
required for these patients (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Use in
patients with hepatic impairment has not been studied. Caution and careful dose
titration is recommended when</span><span lang=EN-GB> treating patients with
mild to moderate hepatic impairment. </span><span lang=EN-GB>Use in patients
with severe hepatic impairment is not recommended.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Discontinuation
of rufinamide</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>When rufinamide
treatment is to be discontinued, it should be withdrawn gradually. In clinical
trials rufinamide discontinuation was achieved by reducing the dose by
approximately&nbsp;25% every two days (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>In the case of one or more missed doses, individualised
clinical judgement is necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Uncontrolled open&#8209;label studies
suggest sustained long&#8209;term efficacy, although no controlled study has
been conducted for longer than three months.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of rufinamide in new&#8209;born
infants or infants and toddlers aged less than&nbsp;1&nbsp;year have not been
established. No data are available (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rufinamide
is for oral use.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The tablet
should be taken twice daily with water in the morning and in the evening, in
two equally divided doses.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Inovelon
should be administered with food (see section&nbsp;5.2). If the patient has
difficulty with swallowing, tablets can be crushed and administered in half a
glass of water. Alternatively, use the score line to break the tablet into two
equal halves.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substance, triazole derivatives or to any of the excipients
listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Status
epilepticus</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Status
epilepticus cases have been observed during treatment with rufinamide in clinical
development studies, whereas no such cases were observed with placebo. These
events led to rufinamide discontinuation in&nbsp;20% of the cases. If patients
develop new seizure types and/or experience an increased frequency of status
epilepticus that is different from the patient’s baseline condition, then the
benefit&#8209;risk ratio of the therapy should be reassessed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Withdrawal
of rufinamide</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide should be withdrawn gradually to
reduce the possibility of seizures on withdrawal. </span><span lang=EN-GB>In
clinical studies discontinuation was achieved by reducing the dose by
approximately&nbsp;25% every two days.</span><span lang=EN-GB> There are
insufficient data on the withdrawal of concomitant antiepileptic medicinal
products once seizure control has been achieved with the addition of
rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Central
Nervous System reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide treatment has been associated
with dizziness, somnolence, ataxia and gait disturbances, which could increase
the occurrence of accidental falls in this population (see section&nbsp;4.8).
Patients and carers should exercise caution until they are familiar with the
potential effects of this </span><span lang=EN-GB>medicinal product.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hypersensitivity
reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Serious antiepileptic medicinal product
hypersensitivity syndrome including DRESS (Drug Reaction with Eosinophilia and
Systemic Symptoms) and Stevens&#8209;Johnson syndrome have occurred in
association with rufinamide therapy. Signs and symptoms of this disorder were
diverse; however, patients typically, although not exclusively, presented with
fever and rash associated with other organ system involvement. Other associated
manifestations included lymphadenopathy, liver function tests abnormalities,
and haematuria. As the disorder is variable in its expression, other organ system
signs and symptoms not noted here may occur. The antiepileptic drug (AED)
hypersensitivity syndrome occurred in close temporal association to the
initiation of rufinamide therapy and in the paediatric population. If this
reaction is suspected, rufinamide should be discontinued and alternative
treatment started. All patients who develop a rash while taking rufinamide must
be closely monitored.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>QT
shortening</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In a
thorough QT study, rufinamide produced a decrease in QTc interval proportional
to concentration. Although the underlying mechanism and safety relevance of
this finding is not known, clinicians should use clinical judgment when
assessing whether to prescribe rufinamide to patients at risk from further
shortening their QTc duration (e.g., Congenital Short QT Syndrome or patients
with a family history of such a syndrome).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
childbearing potential</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Women of childbearing potential must use
contraceptive measures during treatment with Inovelon. Physicians should try to
ensure that appropriate contraception is used, and should use clinical
judgement when assessing whether oral contraceptives, or the doses of the oral
contraceptive components, are adequate, based on the individual patients
clinical situation (see sections&nbsp;4.5&nbsp;and&nbsp;4.6).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Lactose</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon contains lactose, therefore
patients with rare hereditary problems of galactose intolerance, the Lapp
lactase deficiency or glucose&#8209;galactose malabsorption should not take
this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Suicidal
ideation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Suicidal ideation and behaviour have been
reported in patients treated with antiepileptic agents in several indications.
A meta&#8209;analysis of randomised placebo&#8209;controlled trials of anti&#8209;epileptic
medicinal products has also shown a small increased risk of suicidal ideation
and behaviour. The mechanism of this risk is not known and the available data
do not exclude the possibility of an increased risk for Inovelon.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore patients should be monitored for
signs of suicidal ideation and behaviours and appropriate treatment should be
considered. Patients (and caregivers of patients) should be advised to seek
medical advice should signs of suicidal ideation or behaviour emerge.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Potential
for other medicinal products to affect rufinamide</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Other
antiepileptic medicinal products</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rufinamide
concentrations are not subject to clinically relevant changes on co&#8209;administration
with known enzyme inducing antiepileptic medicinal products.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For patients
on Inovelon treatment who have administration of valproate initiated,
significant increases in rufinamide plasma concentrations may occur. Therefore,
consideration should be given to a dose reduction of Inovelon in patients who
are initiated on valproate therapy (see section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The addition or withdrawal of these
medicinal products or adjusting of the dose of these medicinal products during
rufinamide therapy may require an adjustment in dosage of rufinamide (see
section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No significant changes in rufinamide
concentration are observed following co&#8209;administration with lamotrigine,
topiramate or benzodiazepines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Potential for rufinamide to affect other
medicinal products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Other antiepileptic medicinal products</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic interactions between
rufinamide and other antiepileptic medicinal products have been evaluated in
patients with epilepsy, using population pharmacokinetic modelling. Rufinamide
appears not to have a clinically relevant effect on carbamazepine, lamotrigine,
phenobarbital, topiramate, phenytoin or valproate steady state concentrations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Oral contraceptives</span></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Co&#8209;administration of rufinamide&nbsp;800&nbsp;mg twice daily
and </span><span lang=EN-GB>a combined oral contraceptive</span><span
lang=EN-GB> (ethinyloestradiol&nbsp;35&nbsp;&#956;g and
norethindrone&nbsp;1&nbsp;mg) for&nbsp;14&nbsp;days resulted in a mean decrease
in the ethinyl estradiol AUC<sub>0&#8209;24&nbsp;</sub>of&nbsp;22% and in
norethindrone AUC<sub>0&#8209;24&nbsp;</sub>of&nbsp;14%. Studies with other
oral or implant contraceptives have not been conducted. </span><span
lang=EN-GB>Women of child&#8209;bearing potential using hormonal contraceptives
are advised to use an additional safe and effective contraceptive method</span><span
lang=EN-GB> (see sections&nbsp;4.4&nbsp;and&nbsp;4.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cytochrome
P450&nbsp;enzymes</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rufinamide
is metabolised by hydrolysis, and is not metabolised to any notable degree by
cytochrome P450&nbsp;enzymes. Furthermore, rufinamide does not inhibit the
activity of cytochrome P450&nbsp;enzymes (see section&nbsp;5.2). Thus,
clinically significant interactions mediated through inhibition of cytochrome
P450&nbsp;system by rufinamide are unlikely to occur.<i> </i></span><span
lang=EN-GB>Rufinamide has been shown to induce the cytochrome P450&nbsp;enzyme
CYP3A4&nbsp;and may therefore reduce the plasma concentrations of substances
which are metabolised by this enzyme. The effect was modest to moderate. The
mean CYP3A4&nbsp;activity, assessed as clearance of triazolam, was increased
by&nbsp;55% after&nbsp;11&nbsp;days of treatment with
rufinamide&nbsp;400&nbsp;mg twice daily. The exposure of triazolam was reduced
by&nbsp;36%. Higher rufinamide doses may result in a more pronounced induction.</span><b><i><span
lang=EN-GB> </span></i></b><span lang=EN-GB>It may not be excluded that
rufinamide may also decrease the exposure of substances metabolised by other
enzymes, or transported by transport proteins such as P&#8209;glycoprotein.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that patients treated
with substances that are metabolised by the CYP3A4&nbsp;enzyme system are to be
carefully monitored for two weeks at the start of, or after the end of
treatment with rufinamide, or after any marked change in the dose. A dose
adjustment of the concomitantly administered medicinal product may need to be
considered. These recommendations should also be considered when rufinamide is
used concomitantly with substances with a narrow therapeutic window such as
warfarin and digoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A specific interaction study in healthy
subjects revealed no influence of rufinamide at a dose of&nbsp;400&nbsp;mg twice
daily on the pharmacokinetics of olanzapine, a CYP1A2&nbsp;substrate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No data on the interaction of rufinamide
with alcohol are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Risk
related to epilepsy and antiepileptic medicinal products in general:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>It has been shown that in the offspring of
women with epilepsy, the prevalence of malformations is two to three times
greater than the rate of approximately&nbsp;3% in the general population. In
the treated population, an increase in malformations has been noted with
polytherapy; however, the extent to which the treatment and/or the illness is
responsible has not been elucidated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Moreover, effective antiepileptic therapy should
not be interrupted abruptly, since the aggravation of the illness is
detrimental to both the mother and the foetus. AED treatment during pregnancy
should be carefully discussed with the treating physician.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Risk
related to rufinamide:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Studies in animals revealed no teratogenic
effect, but foetotoxicity in the presence of maternal toxicity was observed (see
section&nbsp;5.3). The potential risk for humans is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For rufinamide, no clinical data on exposed
pregnancies are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Taking these data into consideration,
rufinamide should not be used during pregnancy, or in women of childbearing age
not using contraceptive measures, unless clearly necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Women of childbearing potential must use contraceptive
measures during treatment with rufinamide. Physicians should try to ensure that
appropriate contraception is used, and should use clinical judgement when
assessing whether oral contraceptives, or the doses of the oral contraceptive
components, are adequate based on the individual patients clinical situation
(see sections&nbsp;4.4&nbsp;and&nbsp;4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If women treated with rufinamide plan to
become pregnant, the continued use of this product should be carefully weighed.
During pregnancy, interruption of an effective antiepileptic can be detrimental
to both the mother and the foetus if it results in aggravation of the illness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>It is not
known if rufinamide is excreted in human breast milk. Due to the potential
harmful effects for the breast&#8209;fed infant, breast&#8209;feeding should be
avoided during maternal treatment with rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>No data are available on the effects on
fertility following treatment with rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;page-break-after:
avoid'><b><span lang=EN-GB>4.7<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon may cause dizziness, somnolence
and blurred vision. Depending on the individual sensitivity, rufinamide may
have a minor to major influence on the ability to drive and use machines. </span><span
lang=EN-GB>Patients must be advised to exercise caution during activities
requiring a high degree of alertness, e.g., driving or operating machinery.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The clinical
development program has included over&nbsp;1,900&nbsp;patients, with different
types of epilepsy, exposed to rufinamide. The most commonly reported adverse
reactions overall were headache, dizziness, fatigue, and somnolence. The most
common adverse reactions observed at a higher incidence than placebo in
patients with Lennox&#8209;Gastaut syndrome were somnolence and vomiting.
Adverse reactions were usually mild to moderate in severity. The
discontinuation rate in Lennox&#8209;Gastaut syndrome due to adverse reactions
was&nbsp;8.2% for patients receiving rufinamide and&nbsp;0% for patients
receiving placebo. The most common adverse reactions resulting in
discontinuation from the rufinamide treatment group were rash and vomiting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions reported with an
incidence greater than placebo, during the Lennox&#8209;Gastaut syndrome double&#8209;blind
studies or in the overall rufinamide&#8209;exposed population, are listed in
the table below by MedDRA preferred term, system organ class and by frequency.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Frequencies are defined as: very common
(&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10),
uncommon&nbsp;(&#8805;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100),</span><span
lang=EN-GB> rare (&#8805;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=539
 style='margin-left:.75pt;border-collapse:collapse'>
 <thead>
  <tr style='height:.25in'>
   <td width=106 valign=bottom style='width:79.35pt;border:solid windowtext 1.0pt;
   padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>System
   Organ Class</span></b></p>
   </td>
   <td width=113 nowrap valign=bottom style='width:85.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Very
   Common</span></b></p>
   </td>
   <td width=121 nowrap valign=bottom style='width:90.8pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Common</span></b></p>
   </td>
   <td width=113 nowrap valign=bottom style='width:85.05pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon</span></b></p>
   </td>
   <td width=85 nowrap valign=bottom style='width:63.8pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rare</span></b></p>
   </td>
   <td style='height:.25in;border:none' width=0 height=24></td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=6 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width=113 nowrap rowspan=6 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pneumonia</span></p>
  </td>
  <td width=113 nowrap rowspan=6 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=6 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Influenza</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nasopharyngitis</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ear
  infection</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Sinusitis</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rhinitis</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:27.75pt'>
  <td width=106 valign=top style='width:79.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border:none;border-right:
  solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity*</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:27.75pt;border:none' width=0 height=37></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=2 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-bottom:solid black 1.0pt;padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=2 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Eating
  disorder</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Decreased
  appetite</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=3 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Psychiatric
  disorders</span></p>
  </td>
  <td width=113 nowrap rowspan=3 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Anxiety</span></p>
  </td>
  <td width=113 nowrap rowspan=7 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=7 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Insomnia</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=4 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Somnolence*</span></p>
  </td>
  <td width=121 rowspan=2 valign=top style='width:90.8pt;border:none;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Status
  epilepticus*</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Convulsion</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Coordination
  Abnormal*</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nystagmus</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.0pt'>
  <td width=113 rowspan=3 valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:40.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Headache</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dizziness*</span></p>
  </td>
  <td style='height:40.0pt;border:none' width=0 height=53></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Psychomotor
  hyperactivity</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tremor</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:39.75pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:39.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Eye
  Disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 nowrap valign=top style='width:90.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Diplopia</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vision
  blurred</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:39.75pt;border:none' width=0 height=53></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 valign=top style='width:79.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ear and
  Labyrinth disorders</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 nowrap valign=top style='width:90.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vertigo</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;
  height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:39.0pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Epistaxis</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:39.0pt;border:none' width=0 height=52></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=4 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nausea</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Abdominal
  pain upper</span></p>
  </td>
  <td width=113 nowrap rowspan=4 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=4 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vomiting</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Constipation</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=113 nowrap rowspan=2 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dyspepsia</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Diarrhoea</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;Hepatic
  enzyme increase</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=3 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=113 nowrap rowspan=3 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rash*</span></p>
  </td>
  <td width=113 nowrap rowspan=3 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=3 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Acne</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:38.25pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue and bone disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Back pain</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:38.25pt;border:none' width=0 height=51></td>
 </tr>
 <tr style='height:29.25pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Reproductive
  system and breast disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Oligomenorrhoea</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:29.25pt;border:none' width=0 height=39></td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.25pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>General disorders and administration site
  conditions</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Fatigue</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Gait disturbance*</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:38.25pt;border:none' width=0 height=51></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Weight decrease</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <h4 align=left style='text-align:left'><span lang=EN-GB style='font-weight:
  normal'>&nbsp;</span></h4>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=2 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Injury, poisoning and procedural
  complications </span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Head injury</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=2 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Contusion</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>*Cross reference to section&nbsp;4.4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Additional information on special
populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
Population (age&nbsp;1&nbsp;to less than&nbsp;4&nbsp;years)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In a multicentre, open&#8209;label study
comparing the addition of rufinamide to any other AED of the investigator’s
choice to the existing regimen of&nbsp;1&nbsp;to&nbsp;3&nbsp;AEDs in paediatric
patients,&nbsp;1&nbsp;to less than&nbsp;4&nbsp;years of age with inadequately
controlled LGS,&nbsp;25&nbsp;patients, of which&nbsp;10&nbsp;subjects were aged&nbsp;1&nbsp;to&nbsp;2&nbsp;years,
were exposed to rufinamide as adjunctive therapy for&nbsp;24&nbsp;weeks at a
dose of up to&nbsp;45&nbsp;mg/kg/day, in&nbsp;2&nbsp;divided doses. The most
frequently reported TEAEs in the rufinamide treatment group (occurring in
&#8805;&nbsp;10% of subjects) were upper respiratory tract infection and
vomiting (28.0% each), pneumonia and somnolence (20.0% each), sinusitis, otitis
media, diarrhoea, cough and pyrexia (16.0% each), and bronchitis, constipation,
nasal congestion, rash, irritability and decreased appetite (12.0% each). The
frequency, type and severity of these adverse reactions were similar to that in
children&nbsp;4&nbsp;years of age and older, adolescents and adults. Age
characterisation in patients less than&nbsp;4&nbsp;years was not identified in
the limited safety database due to small number of patients in the study.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via the national reporting
system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>After an
acute overdose, the stomach may be emptied by gastric lavage or by induction of
emesis. There is no specific antidote for rufinamide. Treatment should be
supportive and may include haemodialysis (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Multiple dosing of&nbsp;7,200&nbsp;mg/day
was associated with no major signs or symptoms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: antiepileptics, carboxamide derivatives; ATC code: N03AF03.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide modulates the activity of sodium
channels, prolonging their inactive state. Rufinamide is active in a range of
animal models of epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
experience</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon (rufinamide tablets) was
administered in a double blind, placebo&#8209;controlled study, at doses of up
to&nbsp;45&nbsp;mg/kg/day for&nbsp;84&nbsp;days, to&nbsp;139&nbsp;patients with
inadequately controlled seizures associated with Lennox&#8209;Gastaut Syndrome
(including both atypical absence seizures and drop attacks). Male and female
patients (between&nbsp;4&nbsp;and&nbsp;30&nbsp;years of age) were eligible if
they had a history of multiple seizure types, which had to include atypical
absence seizures and drop attacks (i.e., tonic–atonic or astatic seizures); were
being treated with&nbsp;1&nbsp;to&nbsp;3&nbsp;concomitant fixed dose
antiepileptic medicinal products; a minimum of&nbsp;90&nbsp;seizures in the
month before the&nbsp;28&#8209;day baseline period; an EEG within&nbsp;6&nbsp;months
of study entry demonstrating a pattern of slow spike&#8209;and&#8209;wave
complexes (2.5&nbsp;Hz); a weight of at least&nbsp;18&nbsp;kg; and a CT scan or
MRI study confirming the absence of a progressive lesion. All seizures were
classified according to the International League Against Epilepsy Revised
Classification of Seizures. As it is difficult for caregivers to precisely
separate tonic and atonic seizures, the international expert panel of child
neurologists agreed to group these seizure types and call them tonic–atonic
seizures or “drop attacks”. As such, drop attacks were used as one of the
primary end points. A significant improvement was observed for all three
primary variables: the percentage change in total seizure frequency per&nbsp;28&nbsp;days
during the maintenance phase relative to baseline (&#8209;35.8% on Inovelon vs.
–1.6% on placebo, p=0.0006), the number of tonic&#8209;atonic seizures (&#8209;42.9%
on Inovelon vs.&nbsp;2.2% on placebo, p=0.0002), and the seizure severity
rating from the Global Evaluation performed by the parent/guardian at the end
of the double&#8209;blind phase (much or very much improved in&nbsp;32.2% on
Inovelon vs.&nbsp;14.5% on the placebo arm, p=0.0041).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Additionally, Inovelon (rufinamide oral
suspension) was administered in a multicentre, open&#8209;label study comparing
the addition of rufinamide to the addition of any other AED of the
investigator’s choice to the existing regimen of&nbsp;1&nbsp;to&nbsp;3&nbsp;AEDs
in paediatric patients,&nbsp;1&nbsp;to less than&nbsp;4&nbsp;years of age with
inadequately controlled LGS. In this study,&nbsp;25&nbsp;patients were exposed
to rufinamide as adjunctive therapy for&nbsp;24&nbsp;weeks at a dose of up
to&nbsp;45&nbsp;mg/kg/day, in&nbsp;2&nbsp;divided doses. A total of&nbsp;12&nbsp;patients
received any other AED at the investigator’s discretion in the control arm. The
study was mainly designed for safety and not adequately powered to show a
difference with regards to the seizure efficacy variables. The adverse event
profile was similar to that in children&nbsp;4&nbsp;years of age and older,
adolescents, and adults. In </span><span lang=EN-GB>addition, the study investigated
the cognitive development, behaviour and language development of subjects
treated with rufinamide compared to subjects receiving any&#8209;other&#8209;AED.
The Least Square mean change of the Child Behaviour Checklist (CBCL) Total
Problems score after&nbsp;2&nbsp;years of treatment were&nbsp;53.75&nbsp;for
the any other AED group and&nbsp;56.35&nbsp;for the rufinamide group (LS mean
difference [95% CI] +2.60&nbsp;[&#8209;10.5,15.7]; p=0.6928), and the
difference between treatments was &#8209;2.776&nbsp;(95% CI: &#8209;13.3,&nbsp;7.8,
p=0.5939).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic/pharmacodynamic
modelling demonstrated that the reduction of total and tonic&#8209;atonic
seizure frequencies, the improvement of the global evaluation of seizure
severity and the increase in probability of reduction of seizure frequency were
dependent on rufinamide concentrations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Maximum
plasma levels are reached approximately&nbsp;6&nbsp;hours after administration.
Peak concentration (C<sub>max</sub>) and plasma AUC of rufinamide increase less
than proportionally with doses in both fasted and fed healthy subjects and in
patients, probably due to dose&#8209;limited absorption behaviour. After single
doses, food increases the bioavailability (AUC) of rufinamide by
approximately&nbsp;34% and the peak plasma concentration by&nbsp;56%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon oral suspension and Inovelon film&#8209;coated
tablets have been demonstrated to be bioequivalent.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In <i>in &#8209;vitro</i> studies, only a
small fraction of rufinamide (34%) was bound to human serum proteins with
albumin accounting for approximately&nbsp;80% of this binding. This indicates
minimal risk of drug&#8209;drug interactions by displacement from binding sites
during concomitant administration of other substances. Rufinamide was evenly
distributed between erythrocytes and plasma.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide is almost exclusively eliminated
by metabolism. The main pathway of metabolism is hydrolysis of the
carboxylamide group to the pharmacologically inactive acid derivative
CGP&nbsp;47292. Cytochrome P450&#8209;mediated metabolism is very minor. The
formation of small amounts of glutathione conjugates cannot be completely
excluded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide has demonstrated little or no
significant capacity <i>in &#8209;vitro</i> to act as a competitive or
mechanism&#8209;based inhibitor of the following human P450&nbsp;enzymes:
CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5&nbsp;or CYP4A9/11&#8209;2.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The plasma
elimination half&#8209;life is approximately&nbsp;6&#8209;10&nbsp;hours in
healthy subjects and patients with epilepsy. When given twice daily at&nbsp;12&#8209;hourly
intervals, rufinamide accumulates to the extent predicted by its terminal half&#8209;life,
indicating that the pharmacokinetics of rufinamide are time&#8209;independent
(i.e. no autoinduction of metabolism).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a radiotracer study in three healthy
volunteers, the parent compound (rufinamide) was the main radioactive component
in plasma, representing about&nbsp;80% of the total radioactivity, and the
metabolite CGP&nbsp;47292&nbsp;constituting only about&nbsp;15%. Renal
excretion was the predominant route of elimination for active substance related
material, accounting for&nbsp;84.7% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Linearity/non&#8209;linearity:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The bioavailability of rufinamide is
dependent on dose. As dose increases, the bioavailability decreases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pharmacokinetics
in special patient groups</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Sex</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Population
pharmacokinetic modelling has been used to evaluate the influence of sex on the
pharmacokinetics of rufinamide. Such evaluations indicate that sex does not
affect the pharmacokinetics of rufinamide to a clinically relevant extent.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
pharmacokinetics of a single&nbsp;400&nbsp;mg dose of rufinamide were not
altered in subjects with chronic and severe renal failure compared to healthy
volunteers. However, plasma levels were reduced by approximately&nbsp;30% when
haemodialysis was applied after administration of rufinamide, suggesting that
this may be a useful procedure in case of overdose (see
sections&nbsp;4.2&nbsp;and&nbsp;4.9).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No studies
have been performed in patients with hepatic impairment and therefore Inovelon
should not be administered to patients with severe hepatic impairment (see
section&nbsp;4.2).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A pharmacokinetic study in older healthy
volunteers did not show a significant difference in pharmacokinetic parameters
compared with younger adults.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Children
(1&#8209;12&nbsp;years)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Children generally have lower clearance of
rufinamide than adults, and this difference is related to body size </span><span
lang=EN-GB>with rufinamide clearance increasing with body weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A recent population PK analysis of rufinamide
on data pooled from&nbsp;139&nbsp;subjects (115&nbsp;LGS patients
and&nbsp;24&nbsp;healthy subjects), including&nbsp;83&nbsp;paediatric LGS patients
(10&nbsp;patients aged&nbsp;1&nbsp;to&nbsp;</span><span lang=EN-GB>&lt;&nbsp;2&nbsp;years,&nbsp;14&nbsp;patients
aged&nbsp;2&nbsp;to&nbsp;&lt;&nbsp;4&nbsp;years,&nbsp;14&nbsp;patients
aged&nbsp;4&nbsp;to&nbsp;&lt;&nbsp;8&nbsp;years,&nbsp;21&nbsp;patients
aged&nbsp;8&nbsp;to&nbsp;&lt;&nbsp;12&nbsp;years and&nbsp;24&nbsp;patients aged&nbsp;12&nbsp;to&nbsp;&lt;&nbsp;18&nbsp;years)
indicated that when rufinamide is dosed on a mg/kg/day basis in LGS subjects
aged&nbsp;1&nbsp;to &lt;&nbsp;4&nbsp;years, comparable exposure to that in LGS patients
aged &#8805;&nbsp;4&nbsp;years, in which efficacy has been demostrated, is
achieved</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Studies in new&#8209;born infants or
infants and toddlers under&nbsp;1&nbsp;year of age have not been conducted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Conventional
safety pharmacology studies revealed no special hazards at clinically relevant
doses.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Toxicities
observed in dogs at levels similar to human exposure at the maximum recommended
dose were liver changes, including bile thrombi, cholestasis and liver enzyme
elevations thought to be related to increased bile secretion in this species.
No evidence of an associated risk was identified in the rat and monkey repeat
dose toxicity studies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In reproductive and developmental toxicity
studies, there were reductions in foetal growth and survival, and some
stillbirths secondary to maternal toxicity. However, no effects on morphology
and function, including learning or memory, were observed in the offspring.
Rufinamide was not teratogenic in mice, rats or rabbits.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The toxicity profile of rufinamide in juvenile
animals was similar to that in adult animals. Decreased body weight gain was
observed in both juvenile and adult rats and dogs. Mild toxicity in the liver
was observed in juvenile as well as in adult animals at exposure levels lower
than or similar to those reached in patients. Reversibility of all findings was
demonstrated after stopping treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide was
not genotoxic and had no carcinogenic potential. An adverse effect not observed
in clinical studies, but seen in animals at exposure levels similar to clinical
exposure levels and with possible relevance to human use, was myelofibrosis of
the bone marrow in the mouse carcinogenicity study. Benign bone neoplasms
(osteomas) and hyperostosis seen in mice were considered a result of the
activation of a mouse specific virus by fluoride ions released during the
oxidative metabolism of rufinamide.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Regarding the
immunotoxic potential, small thymus and thymic involution were observed in dogs
in a&nbsp;13&#8209;week study with significant response at the high dose in
male. In the&nbsp;13&#8209;week study, female bone marrow and lymphoid changes
are reported at the high dose with a weak incidence. </span><span lang=EN-GB>In
rats, decreased cellularity of the bone marrow and thymic atrophy were observed
only in the carcinogenicity study.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Environmental Risk Assessment (ERA):</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Environmental risk assessment studies have
shown that rufinamide is very persistent in the environment (see
section&nbsp;6.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Core</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Lactose
monohydrate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cellulose,
microcrystalline</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Maize starch</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Croscarmellose
sodium</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hypromellose</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Magnesium
stearate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Sodium
laurilsulfate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Silica
colloidal, anhydrous</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Film
coating</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=NL>Hypromellose</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=NL>Macrogols
(8000)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=NL>Titanium
dioxide (E171)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Talc</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ferric oxide
red (E172)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>4&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Do not store above&nbsp;30ºC.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Aluminium/aluminium blisters, packs
of&nbsp;10,&nbsp;30,&nbsp;50,&nbsp;60&nbsp;and&nbsp;100&nbsp;film&#8209;coated
tablets.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.6     </span></b><b><span lang=EN-GB>Special
precautions for disposal</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No special requirements for disposal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product could have potential
risk for the environment. Any unused medicinal product or waste material should
be disposed of in accordance with local requirements (see section&nbsp;5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal>e&#8209;mail: medinfo_de@eisai.net</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/378/001&#8209;005</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/378/006&#8209;010</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/06/378/011&#8209;016</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Date of
first authorisation:&nbsp;16&nbsp;January&nbsp;2007</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Date of
latest renewal:&nbsp;09&nbsp;January&nbsp;2012</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>05/2020</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the European
Medicines Agency http://www.ema.europa.eu.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon&nbsp;40&nbsp;mg/ml oral suspension</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml of oral suspension
contains&nbsp;40&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1&nbsp;bottle of&nbsp;460&nbsp;ml contains&nbsp;18400&nbsp;mg
rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients with known effect</span></u><span
lang=EN-GB>:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each ml of oral suspension contains:</span></p>

<p class=MsoNormal><span lang=EN-GB>1.2&nbsp;mg methyl parahydroxybenzoate
(E218),</span></p>

<p class=MsoNormal><span lang=EN-GB>0.3&nbsp;mg propyl parahydroxybenzoate
(E216),</span></p>

<p class=MsoNormal><span lang=EN-GB>250&nbsp;mg sorbitol (E420)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>White, slightly viscous suspension.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.       CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon is indicated as adjunctive therapy
in the treatment of seizures associated with Lennox&#8209;Gastaut syndrome
(LGS) in patients&nbsp;1&nbsp;year of age and older.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.2     Posology and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Treatment with rufinamide should be
initiated by a physician specialised in paediatrics or neurology with
experience in the treatment of epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon oral suspension and Inovelon film&#8209;coated
tablets may be interchanged at equal doses. Patients should be monitored during
the switch over period.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Use in
children from&nbsp;1 year to less than&nbsp;4 years of age</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
not receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Treatment
should be initiated at a dose of&nbsp;10&nbsp;mg/kg/day (0.25&nbsp;ml/kg/day)
administered in two equally divided doses separated by
approximately&nbsp;12&nbsp;hours. According to clinical response and
tolerability, the dose may be increased by up to&nbsp;10&nbsp;mg/kg/day
(0.25&nbsp;ml/kg/day) every third day to a target dose
of&nbsp;45&nbsp;mg/kg/day (1.125&nbsp;ml/kg/day) administered in two equally
divided doses separated by approximately&nbsp;12&nbsp;hours. For this patient
population, the maximum recommended dose is&nbsp;45&nbsp;mg/kg/day
(1.125&nbsp;ml/kg/day).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>As valproate
significantly decreases clearance of rufinamide, a lower maximum dose of
Inovelon is recommended for patients being co&#8209;administered valproate.
Treatment should be initiated at a dose of&nbsp;10&nbsp;mg/kg/day (0.25&nbsp;ml/kg/day)
administered in two equally divided doses separated by
approximately&nbsp;12&nbsp;hours. According to clinical response and
tolerability, the dose may be increased by up to&nbsp;10&nbsp;mg/kg/day
(0.25&nbsp;ml/kg/day) every third day to a target dose
of&nbsp;30&nbsp;mg/kg/day (0.75&nbsp;ml/kg/day) administered in two equally divided
doses separated by approximately&nbsp;12&nbsp;hours. For this patient
population, the maximum recommended dose is&nbsp;30&nbsp;mg/kg/day (0.75&nbsp;ml/kg/day).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If the
recommended calculated dose of Inovelon is not achievable, the dose should be
given to the nearest&nbsp;0.5&nbsp;ml of rufinamide.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Use in
children&nbsp;4 years of age</span></i></b><i><span lang=EN-GB> </span></i><b><i><span
lang=EN-GB>or older and less than&nbsp;30&nbsp;kg</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
&lt;&nbsp;30&nbsp;kg not receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Treatment
should be initiated at a daily dose of&nbsp;200&nbsp;mg (5&nbsp;ml dosing
suspension given as two&nbsp;2.5&nbsp;ml doses, one in the morning and one in the
evening). According to clinical response and tolerability, the dose may be
increased by&nbsp;200&nbsp;mg/day increments, as frequently as every third day,
up to a maximum recommended dose of&nbsp;1,000&nbsp;mg/day (25&nbsp;ml/day).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Doses of up
to&nbsp;3,600&nbsp;mg/day (90&nbsp;ml/day) have been studied in a limited
number of patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Patients
&lt;&nbsp;30&nbsp;kg also receiving valproate:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>As valproate significantly decreases
clearance of rufinamide, a lower maximum dose of Inovelon is recommended for
patients &lt;&nbsp;30&nbsp;kg being co&#8209;administered valproate. Treatment should
be initiated at a daily dose of&nbsp;200&nbsp;mg. According to clinical
response and tolerability, after a minimum of&nbsp;2&nbsp;days the dose may be
increased by&nbsp;200&nbsp;mg/day, to the maximum recommended dose
of&nbsp;600&nbsp;mg/day (15&nbsp;ml/day).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Use in
adults, adolescents and children&nbsp;4 years of age or older
of&nbsp;30&nbsp;kg or over</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Patients &gt;&nbsp;30&nbsp;kg not
receiving valproate:</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Treatment
should be initiated at a daily dose of&nbsp;400&nbsp;mg (10&nbsp;ml dosing
suspension given as two&nbsp;5&nbsp;ml doses). According to clinical response
and tolerability, the dose may be increased by&nbsp;400&nbsp;mg/day increments,
as frequently as every other day, up to a maximum recommended dose as indicated
in the table below.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Weight
  range</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>30.0&nbsp;–&nbsp;50.0&nbsp;kg</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>50.1&nbsp;–&nbsp;70.0&nbsp;kg</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&#8805;70.1&nbsp;kg</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=135 valign=top style='width:101.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Maximum recommended dose </span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1,800&nbsp;mg/day or</span></p>
  <p class=MsoNormal><span lang=EN-GB>45&nbsp;ml/day</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>2,400&nbsp;mg/day or</span></p>
  <p class=MsoNormal><span lang=EN-GB>60&nbsp;ml/day</span></p>
  </td>
  <td width=135 valign=top style='width:101.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>3,200&nbsp;mg/day or</span></p>
  <p class=MsoNormal><span lang=EN-GB>80&nbsp;ml/day</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Doses of up to&nbsp;4,000&nbsp;mg/day
(100&nbsp;ml/day) in the&nbsp;30&nbsp;&#8209;50&nbsp;kg range
or&nbsp;4,800&nbsp;mg/day (120&nbsp;ml/day) in the over&nbsp;50&nbsp;kg
category have been studied in a limited number of patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Patients &gt;&nbsp;30&nbsp;kg also receiving
valproate:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Treatment should be initiated at a daily dose
of&nbsp;400&nbsp;mg (</span><span lang=EN-GB>10&nbsp;ml dosing suspension given
as two&nbsp;5&nbsp;ml doses)</span><span lang=EN-GB>. According to clinical
response and tolerability, the dose may be increased by&nbsp;</span><span
lang=EN-GB>400&nbsp;mg/day increments, as frequently as every other day, up to
a maximum recommended dose as indicated in the table below.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:26.7pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Weight range</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>30.0&nbsp;–&nbsp;50.0&nbsp;kg</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>50.1&nbsp;–&nbsp;70.0&nbsp;kg</span></p>
  </td>
  <td width=136 valign=top style='width:102.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR>&#8805;70.1&nbsp;kg</span></p>
  </td>
 </tr>
 <tr>
  <td width=136 valign=top style='width:102.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Maximum recommended dose</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1,200&nbsp;mg/day or</span></p>
  <p class=MsoNormal><span lang=EN-GB>30&nbsp;ml/day</span></p>
  </td>
  <td width=136 valign=top style='width:102.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>1,600&nbsp;mg/day or</span></p>
  <p class=MsoNormal><span lang=EN-GB>40&nbsp;ml/day</span></p>
  </td>
  <td width=136 valign=top style='width:102.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>2,200&nbsp;mg/day or</span></p>
  <p class=MsoNormal><span lang=EN-GB>55&nbsp;ml/day</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>There is limited information on the use of
rufinamide in older people. Since the pharmacokinetics of rufinamide are not
altered in older people (see section&nbsp;5.2), dosage adjustment is not
required in patients over&nbsp;65&nbsp;years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>A study in patients with severe renal
impairment indicated that no dose adjustments are required for these patients
(see section&nbsp;5.2).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Use in patients with hepatic impairment has
not been studied. Caution and careful dose titration is recommended when</span><span
lang=EN-GB> treating patients with mild to moderate hepatic impairment. </span><span
lang=EN-GB>Use in patients with severe hepatic impairment is not recommended.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Discontinuation
of rufinamide</span></i></p>

<p class=MsoNormal><span lang=EN-GB>When rufinamide treatment is to be
discontinued, it should be withdrawn gradually. In clinical trials rufinamide
discontinuation was achieved by reducing the dose by approximately&nbsp;25%
every two days (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>In the case of one or more missed doses,
individualised clinical judgement is necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Uncontrolled open&#8209;label studies
suggest sustained long&#8209;term efficacy, although no controlled study has
been conducted for longer than three months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The </span><span lang=EN-GB>safety and </span><span
lang=EN-GB>efficacy of rufinamide in </span><span lang=EN-GB>new&#8209;born
infants or infants and toddlers aged less than&nbsp;1&nbsp;year have not been
established. No data are available </span><span lang=EN-GB>(see section&nbsp;5.2).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide is for oral use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The suspension should be taken twice daily
in the morning and in the evening, in two equally divided doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon should be administered with food
(see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The oral suspension should be shaken
vigorously before every administration. See section&nbsp;6.6&nbsp;for further
details.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The prescribed
dose of Inovelon oral suspension can be administered via an enteral feeding
tube. Follow the manufacturer’s instructions for the feeding tube to administer
the medicine. </span><span lang=EN-GB> </span><span lang=EN>To ensure adequate
dosing, after administration of the oral suspension, the enteral feeding tube
must be flushed at least once with&nbsp;1&nbsp;ml of water.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance,
triazole derivatives or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.4     Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Status
epilepticus</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Status epilepticus cases have been observed
during treatment with rufinamide in clinical development studies, whereas no
such cases were observed with placebo. These events led to rufinamide
discontinuation in&nbsp;20% of the cases. If patients develop new seizure types
and/or experience an increased frequency of status epilepticus that is
different from the patient’s baseline condition, then the benefit&#8209;risk
ratio of the therapy should be reassessed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Withdrawal
of rufinamide</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide should be withdrawn gradually to
reduce the possibility of seizures on withdrawal. </span><span lang=EN-GB>In
clinical studies discontinuation was achieved by reducing the dose by
approximately&nbsp;25% every two days.</span><span lang=EN-GB> There are
insufficient data on the withdrawal of concomitant antiepileptic medicinal
products once seizure control has been achieved with the addition of
rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Central
Nervous System reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide treatment has been associated
with dizziness, somnolence, ataxia and gait disturbances, which could increase
the occurrence of accidental falls in this population (see section&nbsp;4.8).
Patients and carers should exercise caution until they are familiar with the
potential effects of this </span><span lang=EN-GB>medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hypersensitivity
reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Serious antiepileptic medicinal product
hypersensitivity syndrome</span><span lang=EN-GB> </span><span lang=EN-GB>including
DRESS </span><span lang=EN-GB>(Drug Reaction with Eosinophilia and Systemic
Symptoms) </span><span lang=EN-GB>and Stevens&#8209;Johnson syndrome have
occurred in association with rufinamide therapy. Signs and symptoms of this
disorder were diverse; however, patients typically, although not exclusively,
presented with fever and rash associated with other organ system involvement.
Other associated manifestations included lymphadenopathy, liver function tests
abnormalities, and haematuria. As the disorder is variable in its expression,
other organ system signs and symptoms not noted here may occur. </span><span
lang=EN-GB>The antiepileptic drug (AED) hypersensitivity</span><span
lang=EN-GB> syndrome occurred in close temporal association to the initiation
of rufinamide therapy and in the paediatric population. If this reaction is
suspected, rufinamide should be discontinued and alternative treatment started.
All patients who develop a rash while taking rufinamide must be closely
monitored.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>QT
shortening</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In a thorough QT study, rufinamide produced
a decrease in QTc interval proportional to concentration. Although the
underlying mechanism and safety relevance of this finding is not known,
clinicians should use clinical judgment when assessing whether to prescribe
rufinamide to patients at risk from further shortening their QTc duration (e.g.,
Congenital Short QT Syndrome or patients with a family history of such a
syndrome).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
childbearing potential</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Women of
childbearing potential must use contraceptive measures during treatment with
Inovelon. Physicians should try to ensure that appropriate contraception is
used, and should use clinical judgement when assessing whether oral
contraceptives, or the doses of the oral contraceptive components, are adequate,
based on the individual patients clinical situation (see sections&nbsp;4.5&nbsp;and&nbsp;4.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Parahydroxybenzoates</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Inovelon
oral suspension contains parahydroxybenzoates which may cause allergic
reactions (possibly delayed).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Sorbitol</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Inovelon
oral suspension also contains sorbitol and, therefore, should not be administered
to patients with rare hereditary problems of fructose intolerance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Suicidal
ideation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Suicidal ideation and behaviour have been
reported in patients treated with antiepileptic agents in several indications.
A meta&#8209;analysis of randomised placebo&#8209;controlled trials of anti&#8209;epileptic
medicinal products has also shown a small increased risk of suicidal ideation
and behaviour. The mechanism of this risk is not known and the available data
do not exclude the possibility of an increased risk for Inovelon.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therefore patients should be monitored for
signs of suicidal ideation and behaviours and appropriate treatment should be
considered. Patients (and caregivers of patients) should be advised to seek
medical advice should signs of suicidal ideation or behaviour emerge.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Potential
for other medicinal products to affect rufinamide</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Other
antiepileptic medicinal products</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide concentrations are not subject
to clinically relevant changes on co&#8209;administration with known enzyme
inducing antiepileptic medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For patients on Inovelon treatment who have
administration of valproate initiated, significant increases in rufinamide
plasma concentrations may occur. Therefore, consideration should be given to a
dose reduction of Inovelon in patients who are initiated on valproate therapy
(see section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The addition or withdrawal of these
medicinal products or adjusting of the dose of these medicinal products during
rufinamide therapy may require an adjustment in dosage of rufinamide (see
section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No significant changes in rufinamide
concentration are observed following co&#8209;administration with lamotrigine,
topiramate or benzodiazepines.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Potential
for rufinamide to affect other medicinal products</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Other
antiepileptic medicinal products</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetic interactions between
rufinamide and other antiepileptic medicinal products have been evaluated in
patients with epilepsy, using population pharmacokinetic modelling. Rufinamide
appears not to have a clinically relevant effect on carbamazepine, lamotrigine,
phenobarbital, topiramate, phenytoin or valproate steady state concentrations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Oral
contraceptives</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Co&#8209;administration
of rufinamide&nbsp;800&nbsp;mg twice daily and a combined oral contraceptive
(ethinyloestradiol&nbsp;35&nbsp;&#956;g and norethindrone&nbsp;1&nbsp;mg)
for&nbsp;14&nbsp;days resulted in a mean decrease in the ethinyl estradiol AUC<sub>0&#8209;24&nbsp;</sub>of&nbsp;22%
and in norethindrone AUC<sub>0&#8209;24&nbsp;</sub>of&nbsp;14%. Studies with
other oral or implant contraceptives have not been conducted. </span><span
lang=EN-GB>Women of child&#8209;bearing potential using hormonal contraceptives
are advised to use an additional safe and effective contraceptive method</span><span
lang=EN-GB> (see sections&nbsp;4.4&nbsp;and&nbsp;4.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Cytochrome
P450&nbsp;enzymes</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide is metabolised by hydrolysis,
and is not metabolised to any notable degree by cytochrome P450&nbsp;enzymes.
Furthermore, rufinamide does not inhibit the activity of cytochrome
P450&nbsp;enzymes (see section&nbsp;5.2). Thus, clinically significant
interactions mediated through inhibition of cytochrome P450&nbsp;system by
rufinamide are unlikely to occur.<i> </i></span><span lang=EN-GB>Rufinamide has
been shown to induce the cytochrome P450&nbsp;enzyme CYP3A4&nbsp;and may
therefore reduce the plasma concentrations of substances which are metabolised
by this enzyme. The effect was modest to moderate. The mean
CYP3A4&nbsp;activity, assessed as clearance of triazolam, was increased
by&nbsp;55% after&nbsp;11&nbsp;days of treatment with
rufinamide&nbsp;400&nbsp;mg twice daily. The exposure of triazolam was reduced
by&nbsp;36%. Higher rufinamide doses may result in a more pronounced induction.</span><b><i><span
lang=EN-GB> </span></i></b><span lang=EN-GB>It may not be excluded that
rufinamide may also decrease the exposure of substances metabolised by other
enzymes, or transported by transport proteins such as P&#8209;glycoprotein.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that patients treated
with substances that are metabolised by the CYP3A4&nbsp;enzyme system are to be
carefully monitored for two weeks at the start of, or after the end of
treatment with rufinamide, or after any marked change in the dose. A dose
adjustment of the concomitantly administered medicinal product may need to be
considered. These recommendations should also be considered when rufinamide is
used concomitantly with substances with a narrow therapeutic window such as
warfarin and digoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A specific interaction study in healthy
subjects revealed no influence of rufinamide at a dose of&nbsp;400&nbsp;mg twice
daily on the pharmacokinetics of olanzapine, a CYP1A2&nbsp;substrate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No data on the interaction of rufinamide
with alcohol are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Risk
related to epilepsy and antiepileptic medicinal products in general:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>It has been shown that in the offspring of
women with epilepsy, the prevalence of malformations is two to three times
greater than the rate of approximately&nbsp;3% in the general population. In
the treated population, an increase in malformations has been noted with
polytherapy; however, the extent to which the treatment and/or the illness is
responsible has not been elucidated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Moreover, effective antiepileptic therapy should
not be interrupted abruptly, since the aggravation of the illness is
detrimental to both the mother and the foetus.</span><span lang=EN-GB> AED
treatment during pregnancy should be carefully discussed with the treating
physician.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Risk
related to rufinamide:</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Studies in animals revealed no teratogenic
effect, but foetotoxicity in the presence of maternal toxicity </span><span
lang=EN-GB>was observed </span><span lang=EN-GB>(see section&nbsp;5.3). The
potential risk for humans is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For rufinamide, no clinical data on exposed
pregnancies are available.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Taking these data into consideration,
rufinamide should not be used during pregnancy, or in women of childbearing age
not using contraceptive measures, unless clearly necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Women of childbearing potential must use
contraceptive measures during treatment with rufinamide. Physicians should try
to ensure that appropriate contraception is used, and should use clinical
judgement when assessing whether oral contraceptives, or the doses of the oral
contraceptive components, are adequate based on the individual patients
clinical situation (see sections&nbsp;4.4&nbsp;and&nbsp;4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If women treated with rufinamide plan to
become pregnant, the continued use of this product should be carefully weighed.
During pregnancy, interruption of an effective antiepileptic can be detrimental
to both the mother and the foetus if it results in aggravation of the illness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>It is not known if rufinamide is excreted
in human breast milk. Due to the potential harmful effects for the breast&#8209;fed
infant, breast&#8209;feeding should be avoided during maternal treatment with
rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>No data are available on the effects on
fertility following treatment with rufinamide.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon may cause dizziness, somnolence
and blurred vision. Depending on the individual sensitivity, rufinamide may
have a minor to major influence on the ability to drive and use machines. </span><span
lang=EN-GB>Patients must be advised to exercise caution during activities
requiring a high degree of alertness, e.g., driving or operating machinery.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The clinical development program has
included over&nbsp;1,900&nbsp;patients, with different types of epilepsy,
exposed to rufinamide. The most commonly reported adverse reactions overall
were headache, dizziness, fatigue, and somnolence. The most common adverse
reactions observed at a higher incidence than placebo in patients with Lennox&#8209;Gastaut
syndrome were somnolence and vomiting. Adverse reactions were usually mild to
moderate in severity. The discontinuation rate in Lennox&#8209;Gastaut syndrome
due to adverse reactions was&nbsp;8.2% for patients receiving rufinamide
and&nbsp;0% for patients receiving placebo. The most common adverse reactions
resulting in discontinuation from the rufinamide treatment group were rash and
vomiting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions reported with an
incidence greater than placebo, during the Lennox&#8209;Gastaut syndrome double&#8209;blind
studies or in the overall rufinamide&#8209;exposed population, are listed in
the table below by MedDRA preferred term, system organ class and by frequency.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Frequencies are defined as: very common
(&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10),
uncommon&nbsp;(&#8805;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000).</span></p>

<p class=MsoNormal style='margin-left:141.75pt;text-indent:-141.75pt'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=539
 style='margin-left:.75pt;border-collapse:collapse'>
 <thead>
  <tr style='height:.25in'>
   <td width=106 valign=bottom style='width:79.35pt;border:solid windowtext 1.0pt;
   padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>System
   Organ Class</span></b></p>
   </td>
   <td width=113 nowrap valign=bottom style='width:85.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Very
   Common</span></b></p>
   </td>
   <td width=121 nowrap valign=bottom style='width:90.8pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Common</span></b></p>
   </td>
   <td width=113 nowrap valign=bottom style='width:85.05pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon</span></b></p>
   </td>
   <td width=85 nowrap valign=bottom style='width:63.8pt;border:solid windowtext 1.0pt;
   border-left:none;padding:.75pt .75pt 0in .75pt;height:.25in'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Rare</span></b></p>
   </td>
   <td style='height:.25in;border:none' width=0 height=24></td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=6 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width=113 nowrap rowspan=6 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pneumonia</span></p>
  </td>
  <td width=113 nowrap rowspan=6 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=6 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Influenza</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nasopharyngitis</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ear
  infection</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Sinusitis</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rhinitis</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:27.75pt'>
  <td width=106 valign=top style='width:79.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border:none;border-right:
  solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity*</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><s><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:27.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:27.75pt;border:none' width=0 height=37></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=2 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-bottom:solid black 1.0pt;padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=113 rowspan=2 valign=top style='width:85.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Anorexia</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=2 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Eating disorder</span></p>
  <p class=MsoNormal><span lang=EN-GB>Decreased appetite</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=3 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width=113 nowrap rowspan=3 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Anxiety</span></p>
  </td>
  <td width=113 nowrap rowspan=3 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=3 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Insomnia</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=6 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Somnolence*</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Status epilepticus*</span></p>
  </td>
  <td width=113 rowspan=6 style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 rowspan=6 style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Headache</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Convulsion</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Dizziness*</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Coordination Abnormal*</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=113 nowrap rowspan=3 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Nystagmus</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Psychomotor hyperactivity</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Tremor</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.5pt'>
  <td width=106 rowspan=2 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  25.5pt'>
  <p class=MsoNormal><span lang=EN-GB>Eye Disorders</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:25.5pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 nowrap valign=top style='width:90.8pt;border:none;border-right:
  solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:25.5pt'>
  <p class=MsoNormal><span lang=EN-GB>Diplopia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Vision blurred</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:25.5pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=2 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:25.5pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:25.5pt;border:none' width=0 height=34></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 nowrap valign=top style='width:90.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 valign=top style='width:79.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Ear and Labyrinth disorders</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 nowrap valign=top style='width:90.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Vertigo</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;
  height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:39.0pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal><span lang=EN-GB>Epistaxis</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:39.0pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:39.0pt;border:none' width=0 height=52></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=3 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Nausea</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Abdominal pain upper</span></p>
  </td>
  <td width=113 nowrap rowspan=3 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=3 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=113 valign=top style='width:85.0pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Vomiting</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Constipation</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.25pt'>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:26.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:26.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Dyspepsia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Diarrhoea</span></p>
  </td>
  <td style='height:26.25pt;border:none' width=0 height=35></td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Hepatobiliary disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;Hepatic enzyme increase</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.75pt'>
  <td width=106 rowspan=2 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:26.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:26.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 rowspan=2 valign=top style='width:90.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:26.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Rash*</span></p>
  <p class=MsoNormal><span lang=EN-GB>Acne</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:26.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=2 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:26.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:26.75pt;border:none' width=0 height=36></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='height:38.25pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Musculoskeletal and connective tissue and
  bone disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Back pain</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:38.25pt;border:none' width=0 height=51></td>
 </tr>
 <tr style='height:29.25pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Reproductive system and breast disorders</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Oligomenorrhoea</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:29.25pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:29.25pt;border:none' width=0 height=39></td>
 </tr>
 <tr style='height:38.25pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=113 valign=top style='width:85.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Fatigue</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Gait
  disturbance*</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:38.25pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:38.25pt;border:none' width=0 height=51></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 valign=top style='width:79.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width=113 nowrap valign=top style='width:85.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Weight decrease</span></p>
  </td>
  <td width=113 nowrap valign=bottom style='width:85.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap valign=bottom style='width:63.8pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=106 rowspan=2 valign=top style='width:79.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:.75pt .75pt 0in .75pt;height:
  12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Injury, poisoning and procedural
  complications </span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=top style='width:85.0pt;border-top:
  none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=121 valign=top style='width:90.8pt;border:none;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Head injury</span></p>
  </td>
  <td width=113 nowrap rowspan=2 valign=bottom style='width:85.05pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 nowrap rowspan=2 valign=bottom style='width:63.8pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=121 valign=top style='width:90.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:.75pt .75pt 0in .75pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB>Contusion</span></p>
  </td>
  <td style='height:12.75pt;border:none' width=0 height=17></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>*Cross reference to section&nbsp;4.4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Additional information on special
populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
Population (age&nbsp;1&nbsp;to less than&nbsp;4&nbsp;years)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In a multicentre, open&#8209;label study
comparing the addition of rufinamide to any other AED of the investigator’s
choice to the existing regimen of&nbsp;1&nbsp;to&nbsp;3&nbsp;AEDs in paediatric
patients,&nbsp;1&nbsp;to less than&nbsp;4&nbsp;years of age with inadequately
controlled LGS,&nbsp;25&nbsp;patients, of which&nbsp;10&nbsp;subjects were aged&nbsp;1&nbsp;to&nbsp;2&nbsp;years,
were exposed to rufinamide as adjunctive therapy for&nbsp;24&nbsp;weeks at a
dose of up to&nbsp;45&nbsp;mg/kg/day, in&nbsp;2&nbsp;divided doses. The most
frequently reported TEAEs in the rufinamide treatment group (occurring in
&#8805;&nbsp;10% of subjects) were upper respiratory tract infection and
vomiting (28.0% each), pneumonia and somnolence (20.0% each), sinusitis, otitis
media, diarrhoea, cough and pyrexia (16.0% each), and bronchitis, constipation,
nasal congestion, rash, irritability and decreased appetite (12.0% each). The
frequency, type and severity of these adverse reactions were similar to that in
children&nbsp;4&nbsp;years of age and older, adolescents and adults. Age
characterisation in patients less than&nbsp;4&nbsp;years was not identified in
the limited safety database due to small number of patients in the study.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via the national reporting system listed in </span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After an acute overdose, the stomach may be
emptied by gastric lavage or by induction of emesis. There is no specific
antidote for rufinamide. Treatment should be supportive and may include
haemodialysis (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Multiple dosing of&nbsp;7,200&nbsp;mg/day
was associated with no major signs or symptoms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: antiepileptics,
carboxamide derivatives; ATC code: N03AF03.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide modulates the activity of sodium
channels, prolonging their inactive state. Rufinamide is active in a range of
animal models of epilepsy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
experience</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon (rufinamide tablets) was
administered in a double blind, placebo&#8209;controlled study, at doses of up
to&nbsp;45&nbsp;mg/kg/day for&nbsp;84&nbsp;days, to&nbsp;139&nbsp;patients with
inadequately controlled seizures associated with Lennox&#8209;Gastaut Syndrome
(including both atypical absence seizures and drop attacks). </span><span
lang=EN-GB>Male and female patients (between&nbsp;4&nbsp;and&nbsp;30&nbsp;years
of age) were eligible if they had a history of multiple seizure types, which
had to include atypical absence seizures and drop attacks (i.e., tonic–atonic
or astatic seizures); were being treated with&nbsp;1&nbsp;to&nbsp;3&nbsp;concomitant
fixed dose antiepileptic medicinal products; a minimum of&nbsp;90&nbsp;seizures
in the month before the&nbsp;28&#8209;day baseline period; an EEG within&nbsp;6&nbsp;months
of study entry demonstrating a pattern of slow spike&#8209;and&#8209;wave
complexes (2.5&nbsp;Hz); a weight of at least&nbsp;18&nbsp;kg; and a CT scan or
MRI study confirming the absence of a progressive lesion. All seizures were
classified according to the International League Against Epilepsy Revised
Classification of Seizures. As it is difficult for caregivers to precisely
separate tonic and atonic seizures, the international expert panel of child
neurologists agreed to group these seizure types and call them tonic–atonic
seizures or “drop attacks”. As such, drop attacks were used as one of the
primary end points. </span><span lang=EN-GB>A significant improvement was
observed for all three primary variables: the percentage change in total
seizure frequency per&nbsp;28&nbsp;days during the maintenance phase relative
to baseline (&#8209;35.8% on Inovelon vs. –1.6% on placebo, p=0.0006), the
number of tonic&#8209;atonic seizures (&#8209;42.9% on Inovelon vs.&nbsp;2.2%
on placebo, p=0.0002), and the seizure severity rating from the Global
Evaluation performed by the parent/guardian at the end of the double&#8209;blind
phase (much or very much improved in&nbsp;32.2% on Inovelon vs.&nbsp;14.5% on
the placebo arm, p=0.0041).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Additionally, Inovelon (rufinamide oral
suspension) was administered in a multicentre, open&#8209;label study comparing
the addition of rufinamide to the addition of any other AED of the
investigator’s choice to the existing regimen
of&nbsp;1&nbsp;to&nbsp;3&nbsp;AEDs in paediatric patients,&nbsp;1&nbsp;to less
than&nbsp;4&nbsp;years of age with inadequately controlled LGS. In this
study,&nbsp;25&nbsp;patients were exposed to rufinamide as adjunctive therapy
for&nbsp;24&nbsp;weeks at a dose of up to&nbsp;45&nbsp;mg/kg/day,
in&nbsp;2&nbsp;divided doses. A total of&nbsp;12&nbsp;patients received any&#8209;other
AED at the investigator’s discretion in the control arm. The study was mainly
designed for safety and not adequately powered to show a difference with
regards to the seizure efficacy variables. The adverse event profile was
similar to that in children&nbsp;4&nbsp;years of age and older, adolescents,
and adults. In </span><span lang=EN-GB>addition, the study investigated the
cognitive development, behaviour and language development of subjects treated
with rufinamide compared to subjects receiving any&#8209;other&#8209;AED. The
Least Square mean change of the Child Behaviour Checklist (CBCL) Total Problems
score after&nbsp;2&nbsp;years of treatment were&nbsp;53.75&nbsp;for the any
other AED group and&nbsp;56.35&nbsp;for the rufinamide group (LS mean
difference [95% CI] +2.60&nbsp;[&#8209;10.5,15.7]; p=0.6928), and the
difference between treatments was &#8209;2.776&nbsp;(95% CI: &#8209;13.3,&nbsp;7.8,
p=0.5939).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic/pharmacodynamic
modelling demonstrated that the reduction of total and tonic&#8209;atonic
seizure frequencies, the improvement of the global evaluation of seizure
severity and the increase in probability of reduction of seizure frequency were
dependent on rufinamide concentrations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Maximum plasma levels are reached
approximately&nbsp;6&nbsp;hours after administration. Peak concentration (C<sub>max</sub>)
and plasma AUC of rufinamide increase less than proportionally with doses in
both fasted and fed healthy subjects and in patients, probably due to dose&#8209;limited
absorption behaviour. After single doses, food increases the bioavailability
(AUC) of rufinamide by approximately&nbsp;34% and the peak plasma concentration
by&nbsp;56%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon oral suspension and Inovelon film&#8209;coated
tablets have been demonstrated to be bioequivalent.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In <i>in &#8209;vitro</i>
studies, only a small fraction of rufinamide (34%) was bound to human serum
proteins with albumin accounting for approximately&nbsp;80% of this binding.
This indicates minimal risk of drug&#8209;drug interactions by displacement
from binding sites during concomitant administration of other substances.
Rufinamide was evenly distributed between erythrocytes and plasma.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide is almost exclusively eliminated
by metabolism. The main pathway of metabolism is hydrolysis of the
carboxylamide group to the pharmacologically inactive acid derivative
CGP&nbsp;47292. Cytochrome P450&#8209;mediated metabolism is very minor. The
formation of small amounts of glutathione conjugates cannot be completely
excluded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rufinamide has demonstrated little or no
significant capacity <i>in &#8209;vitro</i> to act as a competitive or
mechanism&#8209;based inhibitor of the following human P450&nbsp;enzymes:
CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5&nbsp;or CYP4A9/11&#8209;2.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The plasma elimination half&#8209;life is
approximately&nbsp;6&#8209;10&nbsp;hours in healthy subjects and patients with
epilepsy. When given twice daily at&nbsp;12&#8209;hourly intervals, rufinamide
accumulates to the extent predicted by its terminal half&#8209;life, indicating
that the pharmacokinetics of rufinamide are time&#8209;independent (i.e. no
autoinduction of metabolism).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a radiotracer study in three healthy
volunteers, the parent compound (rufinamide) was the main radioactive component
in plasma, representing about&nbsp;80% of the total radioactivity, and the
metabolite CGP&nbsp;47292&nbsp;constituting only about&nbsp;15%. Renal
excretion was the predominant route of elimination for active substance related
material, accounting for&nbsp;84.7% of the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Linearity/non&#8209;linearity</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The bioavailability of rufinamide is
dependent on dose. As dose increases, the bioavailability decreases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pharmacokinetics
in special patient groups</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Sex</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Population pharmacokinetic modelling has
been used to evaluate the influence of sex on the pharmacokinetics of
rufinamide. Such evaluations indicate that sex does not affect the
pharmacokinetics of rufinamide to a clinically relevant extent.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of a single&nbsp;400&nbsp;mg
dose of rufinamide were not altered in subjects with chronic and severe renal
failure compared to healthy volunteers. However, plasma levels were reduced by
approximately&nbsp;30% when haemodialysis was applied after administration of
rufinamide, suggesting that this may be a useful procedure in case of overdose
(see sections&nbsp;4.2&nbsp;and&nbsp;4.9).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No studies
have been performed in patients with hepatic impairment and therefore Inovelon
should not be administered to patients with severe hepatic impairment (see
section&nbsp;4.2).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>A
pharmacokinetic study in older healthy volunteers did not show a significant
difference in pharmacokinetic parameters compared with younger adults.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Children
(1&#8209;12&nbsp;years)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Children generally have lower clearance of
rufinamide than adults, and this difference is related to body size with
rufinamide clearance increasing with body weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A recent population PK analysis of
rufinamide on data pooled from&nbsp;139&nbsp;subjects (115&nbsp;LGS patients
and&nbsp;24&nbsp;healthy subjects), including&nbsp;83&nbsp;paediatric LGS
patients (10&nbsp;patients aged&nbsp;1&nbsp;to&nbsp;</span><span lang=EN-GB>&lt;&nbsp;2&nbsp;years,&nbsp;14&nbsp;patients
aged&nbsp;2&nbsp;to&nbsp;&lt;&nbsp;4&nbsp;years,&nbsp;14&nbsp;patients
aged&nbsp;4&nbsp;to&nbsp;&lt;&nbsp;8&nbsp;years,&nbsp;21&nbsp;patients
aged&nbsp;8&nbsp;to&nbsp;&lt;&nbsp;12&nbsp;years and&nbsp;24&nbsp;patients aged&nbsp;12&nbsp;to&nbsp;&lt;&nbsp;18&nbsp;years)
indicated that when rufinamide is dosed on a mg/kg/day basis in LGS subjects
aged&nbsp;1&nbsp;to &lt;&nbsp;4&nbsp;years, comparable exposure to that in LGS
patients aged &#8805;&nbsp;4&nbsp;years, in which efficacy has been
demostrated, is achieved</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Studies in new&#8209;born infants or
infants and toddlers under&nbsp;1&nbsp;year of age have not been conducted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Conventional safety pharmacology studies
revealed no special hazards at clinically relevant doses.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Toxicities observed in dogs at levels
similar to human exposure at the maximum recommended dose were liver changes,
including bile thrombi, cholestasis and liver enzyme elevations thought to be
related to increased bile secretion in this species. No evidence of an
associated risk was identified in the rat and monkey repeat dose toxicity
studies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In reproductive and developmental toxicity
studies, there were reductions in foetal growth and survival, and some
stillbirths secondary to maternal toxicity. However, no effects on morphology
and function, including learning or memory, were observed in the offspring.
Rufinamide was not teratogenic in mice, rats or rabbits.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The toxicity profile of rufinamide in
juvenile animals was similar to that in adult animals. Decreased body weight
gain was observed in both juvenile and adult rats and dogs. Mild toxicity in
the liver was observed in juvenile as well as in adult animals at exposure
levels lower than or similar to those reached in patients.</span><span
lang=EN-GB> </span><span lang=EN-GB>Reversibility of all findings was
demonstrated after stopping treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide was
not genotoxic and had no carcinogenic potential. An adverse effect not observed
in clinical studies, but seen in animals at exposure levels similar to clinical
exposure levels and with possible relevance to human use, was myelofibrosis of
the bone marrow in the mouse carcinogenicity study. Benign bone neoplasms
(osteomas) and hyperostosis seen in mice were considered a result of the
activation of a mouse specific virus by fluoride ions released during the
oxidative metabolism of rufinamide.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Regarding the
immunotoxic potential, small thymus and thymic involution were observed in dogs
in a&nbsp;13&#8209;week study with significant response at the high dose in
male. In the&nbsp;13&#8209;week study, female bone marrow and lymphoid changes
are reported at the high dose with a weak incidence.</span><span lang=EN-GB> In
rats, decreased cellularity of the bone marrow and thymic atrophy were observed
only in the carcinogenicity study.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Environmental Risk Assessment (ERA):</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Environmental risk assessment studies have
shown that rufinamide is very persistent in the environment (see
section&nbsp;6.6).</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>6.       PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Microcrystalline
cellulose (E460)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Carmellose
sodium</span><span lang=EN-GB> (E466)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Hydroxyethylcellulose</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Citric acid,
anhydrous (E330)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Simeticone
emulsion,&nbsp;30% containing benzoic acid, cyclotetrasiloxane, dimethicone,
glycol stearate and glyceryl distearate, methylcellulose, PEG&#8209;40&nbsp;stearate
(polyethylene glycol stearate), polysorbate&nbsp;65, silica gel, sorbic acid,
sulphuric acid and water.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Poloxamer&nbsp;188</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Methyl
parahydroxybenzoate (E218)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Propyl
parahydroxybenzoate (E216)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>Propylene
glycol (E1520).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>Potassium
sorbate (E202)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=IT>Sorbitol (E420)</span><span
lang=IT>, liquid (non&#8209;crystallising)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Orange flavour</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Water</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>3&nbsp;</span><span
lang=EN-GB>years.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>After first
opening:&nbsp;90&nbsp;days.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>6.4     Special precautions for
storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>This medicinal
product does not require any special storage conditions. For storage conditions
after first opening of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>6.5     Nature and contents of
container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oriented&#8209;polyethylene
terephthalate (o&#8209;PET) bottle with a child&#8209;resistant polypropylene
(PP) closure; each bottle contains&nbsp;460&nbsp;ml of suspension in an outer
cardboard carton.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Each carton
contains one bottle, two identical calibrated oral dosing syringes and a press&#8209;in&#8209;bottle
adapter (PIBA). The oral dosing syringes are graduated in&nbsp;0.5&nbsp;ml
increments.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>6.6     </span></b><b><span
lang=EN-GB>Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Preparation:
The press&#8209;in&#8209;bottle adapter (PIBA) which is supplied in the product
carton should be inserted firmly into the neck of the bottle before use and
remain in place for the duration of the usage of the bottle. The dosing syringe
should be inserted into the PIBA and the dose withdrawn from the inverted
bottle. The cap should be replaced after each use. The cap fits properly when
the PIBA is in place.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Nasogastric
tube (NG): </span><span lang=EN-GB>Polyvinyl chloride (PVC) tube</span><span
lang=EN-GB> of not greater than&nbsp;40&nbsp;cm</span><span lang=EN-GB> in
length and</span><span lang=EN-GB> diameter of tube</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>5&nbsp;Fr</span><span lang=EN-GB>.</span><span lang=EN-GB> To ensure
adequate dosing, after administration of the oral suspension, the enteral
feeding tube must be flushed at least once with&nbsp;1&nbsp;ml of water.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>No special
requirements for disposal.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>This medicinal
product could have potential risk for the environment. Any unused medicinal
product to waste material should be disposed of in accordance with local
requirements (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION
HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>e&#8209;mail:
medinfo_de@eisai.net</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EU/1/06/378/017</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>9.       DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Date of first
authorisation:&nbsp;16&nbsp;January&nbsp;2007</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Date of latest
renewal:&nbsp;</span><span lang=EN-GB>09&nbsp;January&nbsp;2012</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>05/2020</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the European
Medicines Agency http://www.ema.europa.eu.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>A.      MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
AND USE</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE
SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>E.      SPECIFIC OBLIGATION TO COMPLETE POST&#8209;AUTHORISATION
MEASURES FOR THE MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB>A.      MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></h1>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Name and
address of the manufacturer responsible for batch release</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>Eisai Manufacturing Limited</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>Mosquito Way</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>Hatfield</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>Hertfordshire</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='layout-grid-mode:line'>AL10&nbsp;9SN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>United Kingdom</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Or</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></h1>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section&nbsp;4.2).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></h1>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Periodic
Safety Update Reports</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The marketing
authorisation holder shall submit periodic safety update reports for this
product in accordance with the requirements set out in the list of Union
reference dates (EURD list) provided for under Article&nbsp;107c(7) of
Directive&nbsp;2001/83/EC and published on the European medicines web&#8209;portal.</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></h1>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Risk Management Plan (RMP)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module&nbsp;1.8.2&nbsp;of the Marketing
Authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>An updated RMP
should be submitted:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If the dates
for submission of a PSUR and the update of a RMP coincide, they can be
submitted at the same time.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB>E.      SPECIFIC OBLIGATION TO COMPLETE POST&#8209;AUTHORISATION
MEASURES AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES</span></h1>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1><span lang=EN-GB>A. LABELLING</span></h1>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;100&nbsp;mg
film&#8209;coated tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Each tablet
contains&nbsp;100&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>10</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>10&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>30&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>50</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>50&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>60</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>60&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>100</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>100&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Read the
package leaflet before use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP (MM/YYYY)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not store
above&nbsp;30ºC.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EU/1/06/378/001&#8209;005</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;100&nbsp;mg
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.     UNIQUE IDENTIFIER –&nbsp;2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.     UNIQUE IDENTIFIER &#8209; HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR
STRIPS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;100&nbsp;mg
film&#8209;coated tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       NAME OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Eisai</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;200&nbsp;mg
film&#8209;coated tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Each tablet
contains&nbsp;200&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>10</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>10&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>30&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>50</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>50&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>60</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>60&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>100</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>100&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Read the
package leaflet before use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP (MM/YYYY)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not store
above&nbsp;30ºC.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EU/1/06/378/006&#8209;010</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;200&nbsp;mg
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER –&nbsp;2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR
STRIPS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;200&nbsp;mg
film&#8209;coated tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       NAME OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Eisai</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;400&nbsp;mg
film&#8209;coated tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Each tablet
contains&nbsp;400&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Contains
lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>10</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>10&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>30</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>30&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>50</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>50&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>60</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>60&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>100</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>100&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>200</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>200&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Read the
package leaflet before use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP (MM/YYYY)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not store
above&nbsp;30ºC.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EU/1/06/378/011&#8209;016</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;400&nbsp;mg
tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.     UNIQUE IDENTIFIER –&nbsp;2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.     UNIQUE IDENTIFIER &#8209; HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR
STRIPS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;400&nbsp;mg
film&#8209;coated tablets</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       NAME OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Eisai</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Inovelon&nbsp;40&nbsp;mg/ml
oral suspension</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>1&nbsp;ml of
Inovelon oral suspension contains&nbsp;40&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>1&nbsp;bottle
contains&nbsp;18400&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Also contains
methyl parahydroxybenzoate (E218)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>propyl
parahydroxybenzoate (E216)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>sorbitol (E420)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=PT-BR>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>See leaflet for
further information.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oral
suspension&nbsp;460&nbsp;ml.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Each carton
contains&nbsp;1&nbsp;bottle,&nbsp;2&nbsp;syringes and&nbsp;1&nbsp;press&#8209;in&#8209;bottle
adapter (PIBA).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Read the
package leaflet before use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Shake well
before use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>After first
opening: use within&nbsp;90&nbsp;days.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>EU/1/06/378/017</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER&lt;, DONATION AND PRODUCT CODES&gt;</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Inovelon&nbsp;40&nbsp;mg/ml</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.     UNIQUE IDENTIFIER –&nbsp;2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.     UNIQUE IDENTIFIER &#8209; HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<h1><span lang=EN-GB>B. PACKAGE LEAFLET</span></h1>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Inovelon&nbsp;</span></b><b><span
lang=EN-GB>1</span></b><b><span lang=EN-GB>00&nbsp;mg</span></b><b><span
lang=EN-GB> </span></b><b><span lang=EN-GB>film&#8209;coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Inovelon&nbsp;</span></b><b><span
lang=EN-GB>200&nbsp;mg</span></b><b><span lang=EN-GB> film&#8209;coated tablets</span></b></p>

<p class=MsoNormal style='margin-left:113.4pt;text-indent:28.35pt'><b><span
lang=EN-GB>Inovelon&nbsp;</span></b><b><span lang=EN-GB>400&nbsp;mg</span></b><b><span
lang=EN-GB> film&#8209;coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Rufinamide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully before
you start taking</span></b><b><span lang=EN-GB> </span></b><b><span lang=EN-GB>this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        Keep this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        If you have any further questions, ask the doctor or
pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        This medicine has been prescribed for you only. Do
not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        If you get any side effects, talk to the doctor or
pharmacist. This includes any possible side effects not listed in this leaflet.
See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet</span></b><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1.       What Inovelon is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2.       What you need to know before you take Inovelon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3.       How to use Inovelon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5.       How to store Inovelon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>1.       What Inovelon is and what it is
used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon contains a medicine called
rufinamide. It belongs to a group of medicines called antiepileptics, which are
used to treat epilepsy (a condition where someone has seizures or fits).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon is used with other medicines to treat
seizures associated with Lennox&#8209;Gastaut syndrome in adults, adolescents
and children from&nbsp;1&nbsp;year of age. Lennox&#8209;Gastaut syndrome is the
name given to a group of severe epilepsies in which you may experience repeated
seizures of various types.</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon has been given to you by your
doctor to reduce the number of your seizures or fits.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you take
Inovelon</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Do not take Inovelon:</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        if you are allergic to rufinamide or triazole
derivatives or any of the other ingredients of Inovelon (listed in
section&nbsp;6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor or pharmacist if:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        you have Congenital Short QT Syndrome or a family
history of such a syndrome (electrical disturbance of the heart), as taking
rufinamide could make it worse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        you suffer from liver problems. There is limited
information on the use of rufinamide in this group, so the dose of your
medicine may need to be increased more slowly. If your liver disease is severe
the doctor may decide Inovelon is not recommended for you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        you get a skin rash or fever. These could be signs of
an allergic reaction. See the doctor immediately as very occasionally this may
become serious.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        you suffer an increase in the number or severity or
duration of your seizures, you should contact the doctor immediately if this
happens.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        you experience difficulty walking, abnormal movement,
dizziness or sleepiness inform the doctor, if any of these happen.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you take this medicine and have thoughts of
harming or killing yourself at any time, <b>contact your doctor or go to a
hospital straight away </b>(see section&nbsp;4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Consult the doctor, even if these events
occurred at any time in the past.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Children</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon should not be given to children
younger than&nbsp;1&nbsp;year of age since there is not enough information on
its use in this age group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other medicines and Inovelon</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor or pharmacist if you are
taking or have recently taken any other medicines, including medicines obtained
without a prescription. </span><span lang=EN-GB>If you are taking </span><span
lang=EN-GB>the following medicines: phenobarbital, fosphenytoin, phenytoin or
primidone,</span><span lang=EN-GB> you may need to be carefully monitored for
two weeks at the start of, or after the end of treatment with rufinamide, or
after any marked change in the dose. A change in the dose of the other medicines
may be needed as they may become slightly less effective when given with
rufinamide</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Antiepileptic medicines and Inovelon</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>If the doctor prescribes or recommends an
additional treatment for epilepsy (e.g., valproate) you must tell the doctor
you are taking Inovelon as the dose may need adjusting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adults and children taking valproate at the
same time as rufinamide will result in high levels of rufinamide in the blood. Tell
your doctor if you are taking valproate as the dose of Inovelon may need to be
reduced by your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor if </span><span lang=EN-GB>you
are taking hormonal/oral contraceptives, e.g., </span><span lang=EN-GB>“The
pill”</span><span lang=EN-GB>. Inovelon may make the pill not effective at
preventing pregnancy. Therefore, it is recommended that you use an additional
safe and effective contraceptive method (such as a barrier method, e.g., condoms)
when taking Inovelon.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor if you are taking the blood
thinner – warfarin. The doctor may need to adjust the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor if you are taking digoxin
(a medicine used to treat heart conditions). The doctor may need to adjust the
dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Inovelon
with food and drink</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>See
section&nbsp;3&nbsp;– ‘How to use Inovelon’ for advice on taking Inovelon with
food and drink.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy,
breast&#8209;feeding and fertility</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you are pregnant, or think you might be
pregnant, or are planning to get pregnant, ask the doctor or pharmacist for
advice before taking Inovelon. You must only take Inovelon during your
pregnancy if the doctor tells you to.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You are advised not to breast&#8209;feed
while taking Inovelon,</span><span lang=EN-GB> as it is not known if rufinamide
will be present in breast milk</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are a woman of childbearing age, you
must use contraceptive measures while taking Inovelon.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ask the doctor or pharmacist for advice
before taking any medicine at the same time as Inovelon.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon may make you feel dizzy, drowsy
and affect your vision, particularly at the beginning of treatment or after a
dose increase. If this happens to you, do not drive or operate machinery.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Inovelon
contains lactose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you have
been told by the doctor that you have an intolerance to some sugars, contact
the doctor before taking this medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.       How to use Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always take this medicine exactly as your
doctor has told you. Check with the doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It may take a while to find the best dose
of Inovelon for you. The dose will be calculated for you by the doctor and will
depend on your age, weight and whether you are taking Inovelon with another
medicine called valproate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Children
aged between&nbsp;1 and&nbsp;4 years of age</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
recommended starting dose is&nbsp;10&nbsp;mg for each kilogram of body weight,
each day. Taken in two equal doses, </span><span lang=EN-GB>half in the morning
and the other half in the evening</span><span lang=EN-GB>. The dose will be calculated
for you by the doctor and may be increased by&nbsp;10&nbsp;mg for each kilogram
of body weight, every third day.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The maximum
daily dose will depend on whether or not you are also taking valproate. Maximum
daily dose not taking valproate is&nbsp;45&nbsp;mg for each kilogram of body
weight, each day. Maximum daily dose taking valproate is&nbsp;30&nbsp;mg for
each kilogram of body weight, each day.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Children&nbsp;4
years of age or older weighing less than&nbsp;30&nbsp;kg</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended starting dose
is&nbsp;200&nbsp;mg a day. Taken in two equal doses, </span><span lang=EN-GB>half
in the morning and the other half in the evening</span><span lang=EN-GB>. The
dose will be calculated for you by the doctor and may be increased
by&nbsp;200&nbsp;mg every third day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The maximum daily dose will depend on
whether or not you are also taking valproate. Maximum daily dose not taking
valproate is&nbsp;1,000&nbsp;mg each day. Maximum daily dose taking valproate
is&nbsp;600&nbsp;mg each day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adults,
adolescents and children weighing&nbsp;30&nbsp;kg or over</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended starting dose
is&nbsp;400&nbsp;mg a day. Taken in two equal doses, </span><span lang=EN-GB>half
in the morning and the other half in the evening</span><span lang=EN-GB>. The
dose will be calculated for you by the doctor and may be increased
by&nbsp;400&nbsp;mg every other day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The maximum
daily dose will depend on whether or not you are also taking valproate. Maximum
daily dose not taking valproate is no more than&nbsp;3,200&nbsp;mg, depending
on body weight. Maximum daily dose taking valproate is no more than&nbsp;2,200&nbsp;mg,
depending on body weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some patients may respond to lower doses
and your doctor may adjust the dose depending on how you respond to the
treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you experience side effects, your doctor
may increase the dose more slowly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon tablets must be taken twice daily
with water, in the morning and in the evening. Inovelon should be taken with
food. If you have difficulty swallowing, you can crush the tablet, then mix the
powder in about half a glass (100&nbsp;ml) of water and drink immediately. You
can also break the tablets into two equal halves and swallow with water.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not reduce the dose or stop this
medicine unless the doctor tells you to.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more Inovelon than you should</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you may have taken more Inovelon than
you should, tell the doctor or pharmacist immediately, or contact your nearest
hospital casualty department, taking the medicine with you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If you
forget to take a dose, continue taking the medicine as normal. Do not take a
double dose to make up for forgotten dose. If you miss taking more than one
dose, seek advice from the doctor.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
stop taking Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>If the
doctor advises stopping treatment, </span><span lang=EN-GB>f</span><span
lang=EN-GB>ollow their instructions concerning the gradual reduction of
Inovelon in order to lower the risk of an increase in seizures.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this product, ask the doctor or pharmacist.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, Inovelon can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following side effects can be very
serious:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Rash and/or
fever. These could be signs of an allergic reaction. If they happen to you tell
your doctor or go to a hospital immediately:</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Change in the
types of seizures you experience/more frequent seizures which last a long time
(called status epilepticus). Tell your doctor immediately.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>A small number
of people being treated with antiepileptics such as Inovelon have had thoughts
of harming or killing themselves. If at any time you have these thoughts
contact your doctor immediately (see section&nbsp;2).</span></p>

<p class=MsoNormal style='margin-left:35.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You may experience the following side
effects with this medicine. </span><span lang=EN-GB>Tell the doctor if you have
any of the following:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very common (more
than&nbsp;1&nbsp;in&nbsp;10&nbsp;patients) side effects of Inovelon are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Dizziness,
headache, nausea, vomiting, sleepiness, fatigue.</span></p>

<p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Common (more than&nbsp;1&nbsp;in
a&nbsp;100&nbsp;patients) side effects of Inovelon are:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Problems
associated with nerves including: difficulty walking, abnormal movement,
convulsions/seizures, unusual eye movements, blurred vision, trembling.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Problems
associated with the stomach including: stomach pain, constipation, indigestion,
loose stools (diarrhoea), loss or change in appetite, weight loss.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Infections: ear
infection, flu, nasal congestion, chest infection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>In addition,
patients have experienced: anxiety, insomnia, nose bleeds, acne, rash, back
pain, infrequent periods, bruising, head injury (as a result of accidental
injury during a seizure).</span></p>

<p class=MsoNormal style='margin-left:35.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Uncommon (between&nbsp;1&nbsp;in
a&nbsp;100&nbsp;and&nbsp;1&nbsp;in a&nbsp;1000&nbsp;patients) side effects of
Inovelon are:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Allergic
reactions and an increase in markers of liver function (hepatic enzyme
increase).</span></p>

<p class=MsoNormal style='margin-left:35.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet. You
can also report side effects directly via </span><span lang=EN-GB>the national
reporting system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects, you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.       How to store Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Do not use
this medicine after the expiry date which is stated on the blister and carton.
The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not store above&nbsp;30°C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine if you notice that
the appearance of the medicine has changed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help to protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Inovelon contains</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&#8209;        The
active substance is rufinamide.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB>Each&nbsp;100&nbsp;mg film&#8209;coated tablet contains&nbsp;100&nbsp;mg
of rufinamide.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Each&nbsp;200&nbsp;mg
film&#8209;coated tablet contains&nbsp;200&nbsp;mg of rufinamide.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Each&nbsp;400&nbsp;mg
film&#8209;coated tablet contains&nbsp;400&nbsp;mg of rufinamide.</span></p>

<p class=MsoNormal style='margin-left:21.3pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8209;        The other ingredients are lactose monohydrate,
microcrystalline cellulose, maize starch, croscarmellose sodium, hypromellose,
magnesium stearate, sodium laurilsulfate and colloidal anhydrous silica. The
film&#8209;coating consists of </span><span lang=EN-GB>hypromellose, macrogols
(8000), titanium dioxide (E171), talc and ferric oxide red (E172).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Inovelon looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inovelon&nbsp;100&nbsp;mg tablets are pink,
oval, slightly convex film&#8209;coated tablets, scored on both sides, embossed
‘&#1028;261’ on one side and blank on the other side.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>They are available as </span><span lang=EN-GB>packs
of&nbsp;10,&nbsp;30,&nbsp;50,&nbsp;60&nbsp;and&nbsp;100&nbsp;film&#8209;coated
tablets.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inovelon&nbsp;200&nbsp;mg tablets are pink,
oval, slightly convex film&#8209;coated tablets, scored on both sides, embossed
‘&#1028;262’ on one side and blank on the other side.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>They are available as </span><span lang=EN-GB>packs
of&nbsp;10,&nbsp;30,&nbsp;50,&nbsp;60&nbsp;and&nbsp;100&nbsp;film&#8209;coated
tablets.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inovelon&nbsp;400&nbsp;mg tablets are pink,
oval, slightly convex film&#8209;coated tablets, scored on both sides, embossed
‘&#1028;263’ on one side and blank on the other side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>They are available as </span><span
lang=EN-GB>packs of&nbsp;10,&nbsp;30,&nbsp;50,&nbsp;60</span><span lang=EN-GB>,</span><span
lang=EN-GB>100&nbsp;</span><span lang=EN-GB>and&nbsp;200&nbsp;</span><span
lang=EN-GB>film&#8209;coated tablets.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Marketing Authorisation
Holder:</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=PT-BR>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>e&#8209;mail:
medinfo_de@eisai.net</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Manufacturer:</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Eisai
Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10&nbsp;9SN, UK.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Or</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=EN-GB>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR>Eisai SA/NV</span></p>
  <p class=MsoNormal><span lang=NL>Tél/Tel: +32&nbsp;(0)800&nbsp;158&nbsp;58</span></p>
  <p class=MsoNormal style='margin-right:1.7pt'><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel: +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Vokietija)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Te&#1083;.:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(</span><span lang=EN-GB>&#1043;&#1077;&#1088;&#1084;&#1072;&#1085;&#1080;&#1103;</span><span
  lang=NL>)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT>Eisai SA/NV</span></p>
  <p class=MsoNormal><span lang=PT>Tél/Tel: +32&nbsp;(0)800&nbsp;158&nbsp;58</span></p>
  <p class=MsoNormal><span lang=NL>(Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;eská republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GesmbH organiza&#269;ni složka</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;420&nbsp;242&nbsp;485&nbsp;839</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=EN-GB>(Németország)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai AB</span></p>
  <p class=MsoNormal><span lang=NL>Tlf:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=NL>(Sverige)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Associated Drug Co. Ltd</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +&nbsp;356&nbsp;2277&nbsp;8000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai B.V.</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;31&nbsp;(0)&nbsp;900&nbsp;575&nbsp;3340</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Eesti</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Saksamaa)</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Norge</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai AB</span></p>
  <p class=MsoNormal><span lang=NL>Tlf:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=NL>(Sverige)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Arriani Pharmaceutica</span><span
  lang=PT-BR>l </span><span lang=PT-BR>S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;:
  +&nbsp;30&nbsp;210&nbsp;668&nbsp;3000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Österreich</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GesmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;43&nbsp;(0)&nbsp;1&nbsp;535&nbsp;1980&#8209;0</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>España</span></b></p>
  <p class=MsoNormal><span lang=ES>Eisai Farmacéutica, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +
  (34)&nbsp;91&nbsp;455&nbsp;94&nbsp;55</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Niemcy)</span></p>
  <p class=MsoNormal><span lang=PL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai SAS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tél: + (33)&nbsp;1&nbsp;47&nbsp;67&nbsp;00&nbsp;05</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT>Eisai
  Farmacêtica, Unipessoal Lda</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +&nbsp;351&nbsp;214&nbsp;875&nbsp;540</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Njema&#269;ka)</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>România</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=PT-BR>(Germania)</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=NL style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=EN-GB>(Germany)</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Nem&#269;ija)</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Ísland</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai AB</span></p>
  <p class=MsoNormal><span lang=NL>Sími:
  +&nbsp;46&nbsp;(0)8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=NL>(Svíþjóð)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Slovenská republika</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GesmbH organiza&#269;ni složka</span></p>
  <p class=MsoNormal><span lang=NL>Tel.: +&nbsp;420&nbsp;242&nbsp;485&nbsp;839</span></p>
  <p class=MsoNormal><span lang=NL>(&#268;eská republika)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Italia</span></b></p>
  <p class=MsoNormal><span lang=FI>Eisai S.r.l.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +&nbsp;39&nbsp;02&nbsp;5181401</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE>Eisai AB</span></p>
  <p class=MsoNormal><span lang=DE>Puh/Tel:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=EN-GB>(Ruotsi)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Arriani Pharmaceuticals S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;:
  +&nbsp;30&nbsp;210&nbsp;668&nbsp;3000</span></p>
  <p class=MsoNormal><span lang=EN-GB>(&#917;&#955;&#955;&#940;&#948;&#945;)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Latvija</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(V&#257;cija)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai Europe</span><span lang=EN-GB> </span><span
  lang=EN-GB>Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44&nbsp;(0)208&nbsp;600&nbsp;1400</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal><span lang=EN-GB>05/2020</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this product is
available on the European Medicines Agency website http://www.ema.europa.eu</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=FR>Inovelon&nbsp;40&nbsp;mg/ml
oral suspension</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=FR>Rufinamide</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask the
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to the doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet</span></b><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>1.       What Inovelon is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>2.       What you need to know before you take Inovelon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>3.       How to use Inovelon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>5.       How to store Inovelon</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>1.       What Inovelon is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon contains a medicine called
rufinamide. It belongs to a group of medicines called antiepileptics, which are
used to treat epilepsy (a condition where someone has seizures or fits).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon is used with other medicines to
treat seizures associated with Lennox&#8209;Gastaut syndrome in adults,
adolescents and children from&nbsp;1&nbsp;year of age. </span><span lang=EN-GB>Lennox&#8209;Gastaut
syndrome is the name given to a group of severe epilepsies in which you may
experience repeated seizures of various types.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon has been given to you by your
doctor to reduce the number of your seizures or fits.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>2.       What you need to know before you take
Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take Inovelon:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>&#8209;     if you are allergic to rufinamide or triazole derivatives
or any of the other ingredients of Inovelon (listed in section&nbsp;6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor or pharmacist if:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have Congenital Short QT Syndrome or a
family history of such a syndrome (electrical disturbance of the heart), as
taking rufinamide could make it worse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you suffer from liver problems. There is limited
information on the use of rufinamide in this group, so the dose of your
medicine may need to be increased more slowly. If your liver disease is severe
the doctor may decide Inovelon is not recommended for you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you get a skin rash or fever. These could be
signs of an allergic reaction. See the doctor immediately as very occasionally
this may become serious.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you suffer an increase in the number or severity
or duration of your seizures, you should contact the doctor immediately if this
happens.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you experience difficulty walking, abnormal
movement, dizziness or sleepiness inform the doctor, if any of these happen.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you take this medicine and have thoughts of
harming or killing yourself at any time, <b>contact your doctor or go to a
hospital straight away </b>(see section&nbsp;4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Consult the doctor, even if these events
occurred at any time in the past.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Children</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon should not be given to children
younger than&nbsp;1&nbsp;year of age since there is not enough information on
its use in this age group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor or pharmacist if you are
taking or have recently taken any other medicines, including medicines obtained
without a prescription. </span><span lang=EN-GB>If you are taking </span><span
lang=EN-GB>the following medicines: phenobarbital, fosphenytoin, phenytoin or
primidone, </span><span lang=EN-GB>you may need to be carefully monitored for
two weeks at the start of, or after the end of treatment with rufinamide, or
after any marked change in the dose. A change in the dose of the other
medicines may be needed as they may become slightly less effective when given
with rufinamide</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Antiepileptic
medicines and Inovelon</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>If the doctor prescribes or recommends an
additional treatment for epilepsy (e.g., valproate) you must tell the doctor
you are taking Inovelon as the dose may need adjusting.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adults and children taking valproate at the
same time as rufinamide will result in high levels of rufinamide in the blood. Tell
your doctor if you are taking valproate as the dose of Inovelon may need to be
reduced by your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor if you are taking
hormonal/oral contraceptives, e.g., “The pill”. Inovelon may make the pill not effective
at preventing pregnancy. Therefore, it is recommended that you use an additional
safe and effective contraceptive method (such as a barrier method, e.g., condoms)
when taking Inovelon.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor if you are taking the blood
thinner – warfarin. The doctor may need to adjust the dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell the doctor if you are taking digoxin
(a medicine used to treat heart conditions). The doctor may need to adjust the
dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Inovelon
with food and drink</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>See
section&nbsp;3&nbsp;– ‘How to use Inovelon’ for advice on taking Inovelon with
food and drink.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy,
breast&#8209;feeding and fertility</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are pregnant, or think you might be
pregnant, or are planning to get pregnant, ask the doctor or pharmacist for
advice before taking Inovelon. You must only take Inovelon during your
pregnancy if the doctor tells you to.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You are advised not to breast&#8209;feed
while taking Inovelon, as it is not known if rufinamide will be present in
breast milk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are a woman of childbearing age, you
must use contraceptive measures while taking Inovelon.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ask the doctor or pharmacist for advice
before taking any medicine </span><span lang=EN-GB>at the same time as
Inovelon.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Inovelon may
make you feel dizzy, drowsy and affect your vision, particularly at the
beginning of treatment or after a dose increase. If this happens to you, do not
drive or operate machinery.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Inovelon contains
sorbitol</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Patients with rare, hereditary problems of
fructose intolerance should not take this medicine.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Inovelon
contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate
(E216)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>These ingredients may cause allergic reactions
(possibly delayed).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.       How to use Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always take this medicine exactly as your
doctor has told you. Check with the doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It may take a while to find the best dose
of Inovelon for you. The dose will be calculated for you by the doctor and will
depend on your age, weight and whether you are taking Inovelon with another
medicine called valproate.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Children
aged between&nbsp;1 and 4&nbsp;years of age</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
recommended starting dose is&nbsp;10&nbsp;mg (0.25&nbsp;ml) for each kilogram
of body weight, each day. Taken in two equal doses, </span><span lang=EN-GB>half
in the morning and the other half in the evening</span><span lang=EN-GB>. The
dose will be calculated for you by the doctor and may be increased
by&nbsp;10&nbsp;mg (0.25&nbsp;ml) for each kilogram of body weight, every third
day.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The maximum
daily dose will depend on whether or not you are also taking valproate. Maximum
daily dose not taking valproate is&nbsp;45&nbsp;mg (1.125&nbsp;ml) for each
kilogram of body weight, each day. Maximum daily dose taking valproate
is&nbsp;30&nbsp;mg (0.75&nbsp;ml) for each kilogram of body weight, each day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Children&nbsp;4
years of age or older weighing less than&nbsp;30&nbsp;kg</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The
recommended starting dose is&nbsp;200&nbsp;mg (5&nbsp;ml) a day. Taken in two equal
doses, half in the morning and the other half in the evening. The dose will be calculated
for you by the doctor and may be increased by&nbsp;200&nbsp;mg (5&nbsp;ml) every
third day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The maximum
daily dose will depend on whether or not you are also taking valproate. Maximum
daily dose not taking valproate is&nbsp;1,000&nbsp;mg (25&nbsp;ml) each day. </span><span
lang=EN-GB>Maximum daily dose taking valproate is&nbsp;600&nbsp;mg (15&nbsp;ml)
each day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Adults, </span></u><u><span
lang=EN-GB>adolescents</span></u><u><span lang=EN-GB> and children
weighing&nbsp;30&nbsp;kg or over</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The recommended starting dose
is&nbsp;400&nbsp;mg (10&nbsp;ml) a day. Taken in two equal doses, half in the
morning and the other half in the evening. The dose will be calculated for you
by the doctor and may be increased by&nbsp;400&nbsp;mg (10&nbsp;ml) every other
day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The maximum daily dose will depend on
whether or not you are also taking valproate. Maximum daily dose not taking
valproate is no more than&nbsp;3,200&nbsp;mg (80&nbsp;ml), depending on body
weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>Maximum daily dose taking valproate is</span><span
lang=EN-GB> no more than&nbsp;2,200&nbsp;mg (55&nbsp;ml), depending on body
weight.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Some patients may respond to lower doses</span><span
lang=EN-GB> and your doctor may adjust the dose depending on how you respond to
the treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you experience side effects, your doctor
may increase the dose more slowly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inovelon oral suspension must be taken
twice every day, once in the morning and once in the evening. Inovelon should
be taken with food.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For dosing,
please use the syringe and adaptor provided.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Instructions
on how to use the syringe and adaptor are provided below:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='position:relative;
z-index:251658240'><span style='position:absolute;left:0px;top:-14249px;
width:594px;height:1px'><img width=594 height=1 src="Inovelo_files/image001.jpg"></span></span><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='page-break-after:avoid'><span
lang=EN-GB><img border=0 width=577 height=5 src="Inovelo_files/image002.png"></span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><a name="_Hlk36555298"><span lang=EN-GB>1.  Shake well before use.</span></a></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>2.  </span><span lang=EN-GB>Push down (1) and turn cap (2)
to open bottle</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>3.  Insert adaptor into the neck of the bottle until a
tight seal is made</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>4.  Push plunger of syringe completely down</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>5.  Insert the syringe into the opening of the adaptor
as far as possible.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>6.  Turn upside down and withdraw the prescribed amount
of Inovelon from the bottle.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>7.  Turn upright and remove the syringe. </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>8.  Leave the adaptor in place and replace cap on
bottle. </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>9.  After dose administration, </span><span lang=EN-GB>s</span><span
lang=EN-GB>eparate <a name="_Hlk33740152">barrel and plunger</a>, and fully
immerse both components in HOT soapy water.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>10. Immerse the barrel and plunger in water to remove
any residual detergent, shake off excess water and leave components to air dry.
Do not wipe dry the dispensers.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB>11. </span><span lang=EN-GB>Do not clean and reuse the
syringe after 40 uses, or if the markings on the syringe wash off.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not reduce the dose or stop this
medicine unless the doctor tells you to.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more Inovelon than you should</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you may have taken more Inovelon than
you should, tell the doctor or pharmacist immediately, or contact your nearest
hospital casualty department, taking the medicine with you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you forget to take a dose, continue
taking the medicine as normal. Do not take a double dose to make up for
forgotten dose. If you miss taking more than one dose, seek advice from the
doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
stop taking Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If the doctor advises stopping treatment, </span><span
lang=EN-GB>f</span><span lang=EN-GB>ollow their instructions concerning the
gradual reduction of Inovelon in order to lower the risk of an increase in
seizures.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this product, ask the doctor or pharmacist.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, Inovelon can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following side effects can be very
serious:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Rash and/or
fever. These could be signs of an allergic reaction. If they happen to you tell
your doctor or go to a hospital immediately:</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Change in the
types of seizures you experience/more frequent seizures which last a long time (called
status epilepticus). Tell your doctor immediately.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>A small number
of people being treated with antiepileptics such as Inovelon have had thoughts
of harming or killing themselves. If at any time you have these thoughts
contact your doctor immediately (see section&nbsp;2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>You may
experience the following side effects with this medicine. Tell the doctor if
you have any of the following:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
(more than&nbsp;1&nbsp;in&nbsp;10&nbsp;patients) side effects of Inovelon are:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB>Dizziness, headache, nausea, vomiting, sleepiness, fatigue.</span></p>

<p class=MsoNormal style='margin-left:.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common (more
than&nbsp;1&nbsp;in a&nbsp;100&nbsp;patients) side effects of Inovelon are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Problems
associated with nerves including: difficulty walking, abnormal movement,
convulsions/seizures, unusual eye movements, blurred vision, trembling.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Problems
associated with the stomach including: stomach pain, constipation, indigestion,
loose stools (diarrhoea), loss or change in appetite, weight loss.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Infections: ear
infection, flu, nasal congestion, chest infection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>In addition,
patients have experienced: anxiety, insomnia, nose bleeds, acne, rash, back
pain, infrequent periods, bruising, head injury (as a result of accidental
injury during a seizure).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
(between&nbsp;1&nbsp;in a&nbsp;100&nbsp;and&nbsp;1&nbsp;in a&nbsp;1000&nbsp;patients)
side effects of Inovelon are:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>Allergic
reactions and an increase in markers of liver function (hepatic enzyme
increase).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet. You
can also report side effects directly via </span><span lang=EN-GB>the national
reporting system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects, you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.       How to store Inovelon</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the bottle label and carton. The expiry date refers to
the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any suspension left in the
bottle more than&nbsp;90&nbsp;days after it was first opened, do not use it.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use the suspension if you notice
that the appearance or smell of your medicine has changed. Return the medicine
to the pharmacist.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help to protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Inovelon contains</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is rufinamide. Each
millilitre contains&nbsp;40&nbsp;mg of rufinamide.&nbsp;5&nbsp;ml
contains&nbsp;200&nbsp;mg rufinamide.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are microcrystalline cellulose
and carmellose sodium, anhydrous citric acid, simeticone emulsion&nbsp;30%
(containing benzoic acid, cyclotetrasiloxane, dimethicone, glycol stearate and
glyceryl distearate, methylcellulose, PEG&#8209;40&nbsp;stearate [polyethylene
glycol stearate], polysorbate&nbsp;65, silica gel, sorbic acid, sulphuric acid
and water), poloxamer&nbsp;188, hydroxyethylcellulose, methyl
parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), potassium
sorbate, propylene glycol (E1520), sorbitol, liquid (non&#8209;crystallising),
orange flavour and water.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Inovelon looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inovelon is a white slightly viscous suspension.
It comes in a bottle of&nbsp;460&nbsp;ml with two identical syringes and a push
in bottle adaptor (PIBA). The syringes are graduated in&nbsp;0.5&nbsp;ml increments.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=EN-GB>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT-BR>e&#8209;mail: medinfo_de@eisai.net</span></p>

<p class=MsoNormal><span lang=PT-BR>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Manufacturer:</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Eisai
Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10&nbsp;9SN, UK.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Or</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
lang=EN-GB>Eisai GmbH</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>Edmund-Rumpler-Straße
3&nbsp;&nbsp;&nbsp; </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span lang=DE>60549
Frankfurt am Main</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For any information about this medicinal
product, please contact the local representative of the Marketing Authorisation
Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR>Eisai SA/NV</span></p>
  <p class=MsoNormal><span lang=NL>Tél/Tel: +32&nbsp;(0)800&nbsp;158&nbsp;58</span></p>
  <p class=MsoNormal style='margin-right:1.7pt'><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Vokietija)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Te&#1083;.:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(</span><span lang=EN-GB>&#1043;&#1077;&#1088;&#1084;&#1072;&#1085;&#1080;&#1103;</span><span
  lang=NL>)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT>Eisai SA/NV</span></p>
  <p class=MsoNormal><span lang=PT>Tél/Tel: +32&nbsp;(0)800&nbsp;158&nbsp;58</span></p>
  <p class=MsoNormal><span lang=NL>(Belgique/Belgien)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;eská republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GesmbH organiza&#269;ni složka</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +&nbsp;420&nbsp;242&nbsp;485&nbsp;839</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel.: +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=EN-GB>(Németország)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Danmark</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai AB</span></p>
  <p class=MsoNormal><span lang=NL>Tlf:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=NL>(Sverige)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Associated Drug Co. Ltd</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +&nbsp;356&nbsp;2277&nbsp;8000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai B.V.</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;31&nbsp;(0)&nbsp;900&nbsp;575&nbsp;3340</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Eesti</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel: +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Saksamaa)</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Norge</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai AB</span></p>
  <p class=MsoNormal><span lang=NL>Tlf:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=NL>(Sverige)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Arriani Pharmaceutica</span><span
  lang=PT-BR>l </span><span lang=PT-BR>S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;:
  +&nbsp;30&nbsp;210&nbsp;668&nbsp;3000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Österreich</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GesmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;43&nbsp;(0)&nbsp;1&nbsp;535&nbsp;1980&#8209;0</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>España</span></b></p>
  <p class=MsoNormal><span lang=ES>Eisai Farmacéutica, S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +
  (34)&nbsp;91&nbsp;455&nbsp;94&nbsp;55</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Niemcy)</span></p>
  <p class=MsoNormal><span lang=PL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai SAS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tél: + (33)&nbsp;1&nbsp;47&nbsp;67&nbsp;00&nbsp;05</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=PT>Eisai
  Farmacêtica, Unipessoal Lda</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +&nbsp;351&nbsp;214&nbsp;875&nbsp;540</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Njema&#269;ka)</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>România</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=PT-BR>(Germania)</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=NL style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=EN-GB>(Germany)</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(Nem&#269;ija)</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Ísland</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai AB</span></p>
  <p class=MsoNormal><span lang=NL>Sími:
  +&nbsp;46&nbsp;(0)8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=NL>(Svíþjóð)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Slovenská republika</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GesmbH organiza&#269;ni složka</span></p>
  <p class=MsoNormal><span lang=NL>Tel.: +&nbsp;420&nbsp;242&nbsp;485&nbsp;839</span></p>
  <p class=MsoNormal><span lang=NL>(&#268;eská republika)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Italia</span></b></p>
  <p class=MsoNormal><span lang=FI>Eisai S.r.l.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +&nbsp;39&nbsp;02&nbsp;5181401</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE>Eisai AB</span></p>
  <p class=MsoNormal><span lang=DE>Puh/Tel:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  <p class=MsoNormal><span lang=EN-GB>(Ruotsi)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Arriani Pharmaceuticals S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;:
  +&nbsp;30&nbsp;210&nbsp;668&nbsp;3000</span></p>
  <p class=MsoNormal><span lang=EN-GB>(&#917;&#955;&#955;&#940;&#948;&#945;)</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel:
  +&nbsp;46&nbsp;(0)&nbsp;8&nbsp;501&nbsp;01&nbsp;600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Latvija</span></b></p>
  <p class=MsoNormal><span lang=NL>Eisai GmbH</span></p>
  <p class=MsoNormal><span lang=NL>Tel:
  +&nbsp;49&nbsp;(0)&nbsp;69&nbsp;66&nbsp;58&nbsp;50</span></p>
  <p class=MsoNormal><span lang=NL>(V&#257;cija)</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Eisai Europe</span><span lang=EN-GB> </span><span
  lang=EN-GB>Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44&nbsp;(0)208&nbsp;600&nbsp;1400</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this product is
available on the European Medicines Agency website http://www.ema.europa.eu</span></p>

</div>

</body>

</html>
